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ABSTRACT 
Prevalence of non-alcoholic fatty liver disease (NAFLD) and obesity both in 
the young and adult population is increasing at an alarming rate globally.  
Along with traditional risk factors, such as diet and sedentary life style, 
exposure of environmental chemicals is suspected to be a risk factor for 
metabolic disruption.  Moreover, the ‘fetal basis of adult disease’ hypothesis 
implicates that early life exposure to environmental chemicals is more 
impactful in causing lipid homeostasis disturbances than exposure in maturity.  
Nuclear factor E2 related factor 2 (Nrf2) is a cytoprotective transcription factor 
known to combat oxidative stress.  The contribution of Nrf2 to other cellular 
functions, such as lipid homeostasis relevant to liver and adipose tissue is 
relatively new emerging area.  The work herein assessed the role of Nrf2 in 
augmenting environmental chemical induced NAFLD and adipogenesis.  CD-1 
mice were exposed to bisphenol A (BPA) perinatally and peripubertally until 
age of 5 week at 25 Pg/kg BW/day and effect of this exposure on hepatic lipid 
disturbances was evaluated at pubertal (week 5) and adult age (week 39).  
Developmental exposure of BPA increased hepatic lipid accumulation in both 
young, as well as adult mice.  BPA also increased Nrf2 expression in these 
animals at both ages.  Nrf2 binding to predicted anti-oxidant response 
elements on the Srebp-1c promoter, a master regulator of denovo lipogenesis, 
elucidated a potential regulatory role of Nrf2 in lipogenesis.  BPA exposure 
also increased Nrf2 binding to this new putative ARE by about 2 fold.  
Epigenetic reprogramming of chromatin upon developmental exposure of 
environmental xenobiotics is a potential mechanism for increasing susceptibly 
to diseases, such as like NALFD.  BPA exposure from gestation day 8 through 
purberty caused hypomethylation in select regions of promoters that encode 
for proteins involved in lipogenesis (e.g. Srebp-1c), as well as the antioxidant 
response (e.g. Nrf2).  The work further depicts an undescribed role for Nrf2 in 
the regulation of lipogenesis via regulation of Srebp-1c. 
In connection to the findings above, as well as other findings in our laboratory 
that pointed to Nrf2 having a role in promoting hepatic lipid accumulation, it 
was decided to evaluate whether chemicals that induce lipid accumulation can 
do so in association with Nrf2 activation.  Next, the role of Nrf2 in lipid 
accumulation was further characterized using adipose tissue in presence of 
perfluorooctane sulfonic acid (PFOS).  In rodent and human preadipocytes, 
PFOS exposure elevated adipogenic process by increasing expression of key 
regulators of adipose differentiation.  PFOS-induced adipogenesis was 
associated with increase in Nrf2 expression and its transcriptional activity.        
In conclusion, the environmental contaminants, BPA and PFOS alter lipid 
homeostasis in liver and adipose tissue respectively.  Concurrent increase in 
Nrf2 expression, and its transcription regulation on lipogenic mediators was 
demonstrated. 
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PREFACE 
The following dissertation titled “Role of nuclear factor E2 related factor 2 
(Nrf2) in environmental chemical induced hepatic steatosis and adipogenesis” 
is presented in manuscript format.  There are three manuscripts in this 
dissertation.  First manuscript is a review, prepared for “Int J of Toxicology”, 
and also serves as general background for manuscript two, three.  Manuscript 
two is formatted in “Hepatology” journal style, second manuscript is in 
“Toxicology and Applied Pharmacology (TAAP)” style.  At the end of the 
thesis, there are two ‘appendices’, which present data that has not been 
included in any of the manuscripts, but was generated by student while 
working towards PhD research.   
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ENVIRONMENTAL ORIGIN OF METABOLIC DYSFUNCTION AND 
DISTURBANCES OF LIPID HOMEOSTASIS 
Prajakta C Shimpi, Angela Slitt 
 
Biomedical and Pharmaceutical Sciences, University of Rhode Island, 
Kingston RI, USA 
 
______________________________________________________________ 
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1.1 ABSTRACT: 
 
Prevalence of obesity and its associated metabolic disorders including non-
alcoholic fatty liver disease (NAFLD), are rising at an alarming rate, and hence 
need a careful search for all possible pathogenic factors contributing this 
epidemic.  Although imbalance of energy intake and energy expenditure is 
considered most traditional risk factors for obesity and NAFLD, recently 
“environmental obesogens” hypothesis is the gaining interest in research 
community, which links exposure of environmental chemicals and obesity.  
Terms like toxicants associated fatty liver diseases (TAFLD) are being 
increasingly used.  The current paper has reviewed some the most recent 
findings of these obesogens and TAFLD contributing chemicals which are 
studied in rodent, in-vitro model as well as human correlation studies. 
Chemical exposures during vulnerable windows in development play a critical 
role in etiology of diseases.  This paper reviewed few developmental exposure 
studies, which correlated positive correlation between concentration of 
exposure of these xenobiotic and obesity phenotype both in human and rodent 
model to understand fetal basis of adult diseases.  However, most of studies 
are only demonstrating link of environment and metabolic effect without 
elucidating possible mechanism of pathogenesis.  Further work is required to 
better characterize the molecular targets responsible for environmental origin 
of metabolic dysfunction and disturbances of lipid homeostasis.  
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1.2 Obesity. Globally the rising prevalence of obesity and its associated 
diseases is major public health concern in adult, children as well as adolescent 
population.  According to results from the 2011–2012 National Health and 
Nutrition Examination Survey (NHANES), more than one-third (34.9%) of 
adults were obese in United States (1). Childhood obesity prevalence is also 
increasing at an alarming rate.  It is estimated that 20.5% of adolescents (12-
19 years of age) and 17.7% children (6-11 years age) are obese (2).  Obesity 
is characterized by structural and functional changes to and distribution of 
white adipose tissue (WAT) in body.  Adipose tissue plays a prominent role of 
balancing energy status of the body by storing excess of fat in form of 
triglyceride.  Initially, excess fat is stored in mature adipocyte, and because of 
its plasticity it can expand by undergoing hypertrophy.  Along with hypertrophy, 
hyperplasia of adipocytes, which means increasing number of fat cells through 
differentiation of stem cells to adipocyte lineage, can also contribute for 
disturbances of normal lipogenic and lipolysis process of adipose tissue 
(3).  Apart from considering WAT as fuel storage depot, is also recognized as 
an active endocrine organ because of secretion of hormones and cytokines 
that play crucial role in maintaining of metabolic homeostasis like appetite, 
inflammation and insulin sensitivity (4).  Adipocyte biology is significant to 
pathogenesis of obesity and hence maintenance of normal adipogenesis and 
mature adipocyte is very significant.   Mature adipocytes form from its 
precursor mesenchymal stem cells through adipogenesis process, which 
involves very complex transcriptional cascade regulating programs.  Multiple 
transcription regulators, including CCAAT/ enhancer-binding proteins (CebpD, 
4  
CebpE), and peroxisome proliferator-activated receptor (Ppar-J), are involved 
in inducing adipogenic programming (5). 
 
1.3 Non-alcoholic Fatty Liver Disease (NAFLD). Obesity associated 
disturbance of adipogenesis process has deleterious consequences on insulin 
resistance, which can contribute to pathogenesis of metabolic syndrome 
comprising type-2 diabetes, dyslipidemia, atherosclerosis, hypertension and 
NAFLD.  Prevalence of suspected NAFLD increased from 3.9% in 1988-1994 
to 10.7% in 2007-2010.  Globally, 10-39% and in United States 20% of 
general adult population is suspected to have NAFLD (6).  About 3-17% of 
children in the United States are detected with fatty liver diseases.  As 
expected, nearly 75% adults and 38% children from overweight/ obese BMI 
have NAFLD (7, 8).  NAFLD is a broad spectrum liver disease ranging from 
preliminary hepatic steatosis to more aggressive form of nonalcoholic 
steatohepatitis (NASH), which in turn may lead to cirrhosis and hepatocellular 
carcinoma (HCC).  Although pathogenesis of NAFLD is not well understood, 
globally accepted “two-hit hypothesis” explain the progression of disease.  
“First hit” is associated accumulation of lipids, especially triglycerides, in the 
hepatocytes cytoplasm, contributing to 5% or more of the liver 
weight.  Although steatosis is asymptomatic and reversible, this chronic fat 
accumulation in liver triggers “second hit” covering various inflammatory 
cytokines and oxidative stress.  Steatotic liver is more susceptible for low-
grade inflammation and disease progression like steatohepatitis.  Dyslipidemia 
and lipid deposition in liver are not only involved in first hit of NAFLD.  Non-
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esterified free fatty acids not only contribute to the steatosis, but also in 
hastening the progression to NASH, challenging two-hit hypothesis (9).  
Recent research also points towards “multi-hit theory” as opposed to two hits 
for pathogenesis of NAFLD- reviewed by (10).  Considering the complexity of 
steatogenesis, necroinflammation of the hepatocytes, oxidative stress and 
fibrogenesis, multi-hit theory is being considered more thorough approach 
towards pathogenesis of NAFLD.   
Because of this increasing prevalence, numerous studies are focusing on 
early diagnosis and treatment for NAFLD.  There is no specific biochemical 
marker or serological test for the diagnosis of NAFLD.  Liver biopsy is the gold 
standard for diagnosis and staging of NAFLD, particularly for the diagnosis of 
NASH.  Due to the invasive nature of liver biopsy and risk associated with 
procedure, it cannot be extensively used for large-scale population.  Different 
imaging techniques like ultrasonography (US), computed tomography (CT), 
magnetic resonance imaging and magnetic resonance spectroscopy have 
been approved as noninvasive alternative methods to detect hepatic steatosis 
(11, 12).  Association of NAFLD with cardiovascular disease, type 2 diabetes, 
cirrhosis, and hepatocellular carcinoma along with difficulty in diagnosis and 
lack of exact therapeutic intervention for these conditions make NAFLD a 
serious public health concern. 
There are multiple sources that contribute to the hepatic fatty acid pool. 1) 
Dietary TG that reach the liver as chylomicron particles from the intestine; 2) 
Denovo synthesis in the liver under a transcriptionally regulated process; 3) 
Fatty acid influx into the liver from lipolysis of adipose tissue in obese and 
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insulin-resistant state ; 4) diminished export of lipids from the liver in very-low-
density lipoproteins; and 5) reduced oxidation of fatty acids.  The accumulated 
fatty acids are stored in liver in the form of TG, eventually contributing to 
steatosis. 
NAFLD pathogenesis may involve disturbances of proliferator-activated 
receptor alpha (PparD) and/ or sterol regulatory element binding protein-1c 
(Srebp-1c), transcription factors that control enzymes responsible for oxidation 
and synthesis of fatty acids respectively. The regulation of lipid metabolism in 
liver is usually integrated with adipose tissue.  Both of these organs play a 
very critical role in trafficking and handling of lipid based on energy status of 
the body (13).  Hepatic triglyceride (TG) can transport to adipose tissues in\ 
very low-density lipoprotein where TG can store.  Under hormonal regulation, 
fatty acids are released from adipose tissue and are transported to liver for 
oxidation.  The control of whole body lipid homeostasis is mainly depending on 
efficient regulation of this cycle (14).  Therefore, disturbances at one organ 
lipid homeostasis can have an impact on the other organ.  This is why NAFLD 
prevalence is high in obese population, and it remains major cause of mortality 
and morbidity in obese people. 
 
1.4 Environmental chemicals and adipose tissue lipid alterations. 
Imbalances of energy intake and energy expenditure either because of 
sedentary lifestyle or some genetic predisposition are well-recognized risk 
factors for obesity and NAFLD.  However, increases in rates of health 
concerns like metabolic syndrome and co-ordinate increase in synthetic 
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chemical production, toxic burden in our air, food and water since last few of 
decades, it seems prudent approach to study the effects of the environmental 
chemicals that are found in the majority of people, in increasing obesity 
epidemic.  It has generated significant interest of studying “nontraditional” risk 
factors (e.g., environmental chemicals, stress, micronutrients, gut microbiome) 
to the etiology of these health conditions. Moreover, because of lipophilic 
property of most environmental chemicals like endocrine disruptors (EDC),, 
adipocytes are an obvious target organ for their biological effects (15).  Many 
bioactive EDCs predicted to bioaccumulate in lipid droplets of mature 
adipocyte that can be released into the systemic circulation slowly, which may 
results into chronic exposure of chemical (16). 
Alterations in adipose tissue function can modulate EDC flux from this storage 
depot, thereby influencing the function of other metabolic tissues.  In 2006 
Blumberg and Grun postulated “environmental obesogen hypothesis” 
suggesting possible link between environmental contaminants and the 
epidemic of metabolic disease (17).  Different classes of chemicals have been 
proposed as environmental obesogens.  Some examples include endocrine 
disturbing chemicals (DES: diethylstilbestrol, genestein, BPA: bisphenol A and 
it’s derivatives), organotins (TBT: tributyltin, TPT: triphenyltin, and DBT: 
dibutyltin), organophosphate pesticicdes (parathion, diazinon, chlorpyrifos), 
phthalates (MEHP: mono-ethylhexyl phthalate, DEHP: di-2-ethylhexyl 
phthalate), polyfluoroalkyl chemicals (PFOA: perfluorooctanoic acid, PFNA: 
perfluorononanoic acid, PFOS: perfluorooctane sulfonic acid, and PFHxS: 
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perfluorohexane sulfonic acid), polybrominated diphenyl ethers(PBDE), 
persistent organic pollutant (non-dioxin PCBs, HCB: Hexachlorobenzene , 
DDE: dichlorodiphenyldichloroethylene).  Human get exposed to these 
chemicals on routine basis either through occupational or non-occupational 
means.  Food, water, air contamination is the most common route of 
exposure.  Some chemicals get into food by leaching out of products that food 
and beverages are stored. A prime example is BPA, which is used in 
polycarbonate reusable food and beverage storage containers and the resin 
lining of cans, which can lead to substantial levels of human exposure.  PFAs 
are stain repellent, and also used in firefighting foams, whereas PBDEs are 
primarily used in flame retardant applications for manufacturing household 
rugs, carpets, non-stick utensils and so on (18-21).  Although actual acute 
exposure of chemicals may be at nanomolar or lower concentrations, 
persistent exposure through these routes cannot be ignored.  
In order to assess environmental xenobiotic induced obesogenic effects, 
numerous in-vivo as well as in-vitro approaches have been employed.  Many 
population epidemiological studies have identified intriguing link between 
environmental chemical levels in biological fluids and metabolic syndrome 
parameters.  Importantly, although these human correlation studies provide 
valuable information in predicting the risk associated with xenobiotic exposure, 
precise mechanisms for underlying effects remain largely unknown.  Table 1 
summarizes representative human correlation studies which associate serum, 
urinary, or tissue specific levels of xenobiotic with obesity parameters including 
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BMI, waist circumference, body weight, plasma insulin, leptin levels, systemic 
inflammation and so on (22-31).  Majority of these data are gathered from 
participants of the National Health and Nutrition Examination Surveys 
(NHANES).  
3T3L-1 murine preadipocyte, adipocyte or bone barrow derived mesenchymal 
stem cells (hADSC, mADSC), are most commonly used in-vitro model for 
studying effect environmental chemicals on adipogenesis.  Through in-vitro 
studies, these chemicals are tested for its potential effect on adipogenic 
differentiation and increasing number of fat cells in body. Alteration of 
frequency with which MSCs are induced into adipogenic lineage to form 
preadipocyte and the rate of differentiation of preadipocytes to adipocyte upon 
exposure of these chemicals have been considered as one the possible 
mechanism for their obesogenic nature.  Table 2 enlists in-vitro studies of 
chemicals tested for their adipogenesis potential (32-41).   
For specific chemical induced obesogenic effects, in-vivo studies are also 
conducted.  Food intake, energy expenditure by using metabolic cages, body 
weight, visceral and subcutaneous adipose tissue weight are some of the end 
point considered while designing these in-vivo experiments.  Considering 
adipose tissue as an endocrine organ, serum leptin, adiponectin, cytokine 
levels are also considered as markers of adipose tissue hypertrophy or 
hyperplasia.  Moreover, physiological consequences of the lipid accumulation 
including insulin resistance, glucose tolerance, urinary glucose elimination, 
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serum insulin levels, blood glucose levels, and serum lipid levels are 
measured as advanced markers of obesity. 
1.5 Environmental chemicals and hepatic lipid alterations. Liver is the 
primary line of defense against potentially harmful xenobiotic therefore that is 
target organ, most commonly affected by environmental chemicals.  Attributing 
to the relevance of environmental contaminants in inducing NAFLD in recent 
years, term toxicants associated fatty liver diseases (TAFLD) and it’s sever 
form toxicants associated steatohepatitis (TASH) were coined (42).  As 
reviewed by Kneeman some of the xenobiotics like amiodarone, methotrexate, 
tamoxifen and corticosteroids are implicated as possible contributing factors to 
cause NAFLD (43).  The effect of numerous environmental/ industrial 
chemicals enlisted by The Toxicological Reference Database (ToxRefDB, 
EPA) and Chemical Effects in Biological Systems (CEBS, National Toxicology 
Program) were studied for liver effects.  Hundreds of chemicals including toxic 
heavy metals (lead, mercury, cadmium, chromium), industrial chemicals 
include organoclorine pesticides DDT and dieldrin, perfluolochemicals, 
brominated fire retardants, PCBs, polyaromatic hyrocarbons, polychlorinated 
and polybrominated diaxins and furans, polychlorinated naphthalenes, 
fungicides, insecticides, biphenyls/dioxins, TCDD have potential to modify fat 
metabolism in liver, and hence elevating the susceptibility to NAFLD (44, 45). 
Although lots of chemicals have been suspected for their ability to induce fatty 
liver independently of obesity, very few have been examined in-vivo.  Table 5 
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enlists chemicals which have been tested in in-vitro as well as in-vivo, and 
human correlation studies for their NAFLD inducing abilities.   
As mentioned earlier, diagnosis of NAFLD is difficult and non-invasive 
methods are not as reliable as biopsy, prevalence of NAFLD may be higher 
than anticipated. As listed in table 5, environmental chemicals contribute to the 
epidemic of the NAFLD, and unless disease progresses to advanced stages, 
diagnosis is difficult, this points towards importance of the mechanistic 
investigation of these environmental chemical induced effects.  Few markers 
used in in-vivo studies for NAFLD include hepatic and serum TG, free fatty 
acid levels and oil red o staining of the frozen liver sections. Environmental 
NAFLD warrants detailed mechanism based, and biomarker research in order 
to better predict the prevalence in the population.      
1.6 Mechanisms of the environmental chemical induced lipid 
disturbances. Molecular mechanisms of these environmental exposure 
induced dyslipidemia are largely unknown. Some of these chemicals are 
structural ligands of lipogenic transcription factors whereas some other 
chemicals like EDC interact of with hormone receptors and they mimic 
endogenous hormones and thus disturb the programming of endocrine 
signaling pathways and thus adipose tissue biology (46).   TBT is a Ppar-γ 
ligand and thus stimulate adipogenesis.  Because of having long carbon chain 
in their structure, PFAs mimic fatty acid structures and bind to Ppar-α (47).  
Phenylsulfamide and fungicide tolylfluanid mimic the action of endogenous 
glucocorticoids and function as a glucocorticoids agonist and augment 
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adipogenesis in 3T3-L1 preadipocytes (48).  
Owing to the rising prevalence of the childhood obesity and NAFLD, nutrition 
and exposure to environmental chemicals during critical early life development 
are newly emerging etiological factors of metabolic syndrome (49).  From 
biomonitoring studies, several environmental chemicals that can cause obesity 
in offspring because of gestational exposure were found in humans (49, 50). 
Increasing evidences are being generated from animal studies of in-utero 
exposure to relevant exposure levels of xenobiotics contributing to increase in 
parameters of obesity/ NAFLD (summarized in tables 3, 4 and 5) (45, 51-68). 
From the mechanistic point of view, it is likely that gene-environment 
interactions and epigenetic modification of gene functions by alteration of DNA 
methylation, histone acetylation, and chromatin remodeling that results in 
genetic reprogramming (69).  These epigenetic alterations during a vulnerable 
window of development usually result in non-reversible changes in tissue 
structure and function.  These changes make body sensitize or programmed 
eventually lead to increases incidences of variety of diseases later in life.  This 
hypothesis also referred as “fetal basis of adult diseases” (69).  
For obesogenic compounds, few recent investigations link early epigenetic 
reprogramming of the adipogenic process to the incidence of obesity in adult 
life (37, 70). 
 
1.7 Conclusion: Rising prevalence of dyslipidemic disorders suggests 
etiological factors beyond traditional lifestyle and genetic predisposition.  
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Obesity and NAFLD increase risk of cardiometabolic diseases, as evident from 
overlapping population prevalence.  Moreover treatment of NAFLD is also a 
concern, as currently there are barely any therapies available in market 
targeting specifically on NAFLD/ NASH in people.  Ongoing pharmaceutical 
research on these therapies is also constantly challenged by difficulty of 
diagnosis and unreliable non-invasive tools (71).   
Based on research from government agencies, and also academic findings, 
few of the manufacturing chemicals have been banned for use in some 
countries, however, majority of chemicals listed in this review remain in 
industrial use.  Also, the replacement chemicals being investigated for 
manufacturing use seem to have similar structural and chemical profiles, 
indicating real possibility of these new chemicals also not being risk-free.  
Another issue with few such environmental chemicals is their prolonged half-
life in nature as well as inside the living system.  PFAs exemplify 
bioaccumulating chemicals that are not degraded to inactive form for years in 
the food chain (72).  Overall, rising awareness about environmental chemical 
exposure contribution to the epidemic of obesity/ NAFLD seems imperative.   
More studies are necessary for thorough mechanistic investigation of these 
environmental origins of the childhood and adulthood diseases, so that 
preventive or therapeutic approaches can be guided.   
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2.1 ABSTRACT 
Bisphenol A (BPA) is chemical used in manufacturing of consumer products 
containing polycarbonate and epoxy resins.  In humans, urinary BPA levels 
have been positively associated with general and abdominal obesity, with 
increased adverse liver effects described in children.  Rodent studies have 
demonstrated increased hepatic lipid accumulation after developmental BPA 
exposure.  Nuclear Factor E2-Related Factor 2 (Nrf2) has been recently 
shown to be a possible contributor to hepatic lipid accumulation.  It was 
hypothesized that epigenetic changes occur before BPA-induced steatosis, 
possibility via induction of Nrf2 expression.  Pregnant CD-1 mice were 
administered 25μg BPA/kg/day via osmotic pump, and then after weaning on 
postnatal day 21, the resulting daughters were exposed to BPA via drinking 
water until PND 35. Tissues were collected at postnatal day 32 (Week 5) and 
39 weeks of age and mRNA and protein expression profiling was performed.  
BPA increased hepatic lipid content along with increased pro-lipogenic 
enzyme mRNA and protein expression and induction of Nrf2 protein 
expression at week 39.  Transcription factor binding was assayed in liver  by 
chromatin immunoprecipitation (ChIP) and result showed at week 5 and week 
39 , BPA exposure increased Nrf2 binding to a putative ARE consensus 
sequence in the Srebp-1c promoter. Known Nrf2 activators increased Srebp-
1c promoter reporter activity in HepG2 cells.  Effect on gene specific and CpG 
site specific DNA methylation modification of was assesses by 
immunoprecipation and pyrosequencing respectively. Hypomethylation of the 
Nrf2 and Srebp-1c promoters was observed in livers from offspring that were 
29  
developmentally exposed to BPA.  Overall, the work herein presents new 
findings that developmental BPA exposure induces fat accumulation via 
hypomethylation of key lipogenic genes and promotes Nrf2 binding to the 
Srebp-1c promoter. 
Keywords: BPA, NAFLD, Nrf2, methylation, Srebp-1c, epigenetic 
Abbreviations: Acetyl CoA carboxylase, Acc; antioxidant response element, 
ARE; E2-microglobulin, B2M; Bisphenol A, BPA; chromatin 
immunoprecipitation, ChIP; fatty acid synthase, Fas; gestational day, GD; 
glycerol 3 phosphate acetyl transferase, Gpat; glutamate cysteine ligase, Gclc; 
methylated DNA immunoprecipitation, MeDIP; nonalcoholic fatty liver disease, 
NAFLD; Nuclear factor E2 related factor 2, Nrf2; oil red o, ORO; peroxisome 
proliferated activated receptor, Ppar; phosphate buffered saline, PBS; 
postnatal day, PND; perinatal peripubertal, PNPP; sterol regulatory element 
binding protein 1c, Srebp-1c; tris-buffered saline, TBS 
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2.2 INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) is a broad-spectrum liver disorder.  
American Association for Liver Diseases guidelines define NAFLD as the 
presence of hepatic steatosis with no evidence of hepatocellular injury in the 
form of ballooning of the hepatocytes (1).  In past two decades, NAFLD 
prevalence has risen in adults and children, with suspected NAFLD having 
increased from 3.9% in 1988-1994 to 10.7% in 2007-2010 (2).  In addition to 
more accepted risk factors such as obesity, energy imbalance, and sedentary 
lifestyle (3), drugs and chemicals of environmental exposure have also been 
implicated in increasing predisposition to NAFLD.  Multiple classes of 
chemicals of environmental exposure including pesticides, insecticides, 
dioxins, and polychlorinated biphenyls (PCBs) are potential modifiers of fat 
metabolism in liver, and are suspected to increase the risk for developing 
NAFLD (4, 5). 
Specifically, exposure to Bisphenol A (BPA), a plastics component used in 
manufacturing of polycarbonate and epoxy resins containing plastic bottles, 
food containers, metal cans, and thermal receipts has been recently 
associated with NAFLD (6, 7).  BPA exposure is ubiquitous, and it was 
detected in more than 90% of the urine samples from the US population (8).  
BPA has also been detected in human breast milk, amniotic fluid and cord 
blood samples, which demonstrates the potential for fetal and neonatal 
exposure (9-11).  A positive correlation between urinary BPA levels and 
obesity risk has been reported in adults and children, especially in adolescent 
females (12).  Recently, increased markers for NAFLD were positively 
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associated with urine BPA levels in a small cohort of children (13).  Therefore, 
there is growing health concern for early-life BPA exposure that has not been 
fully addressed (14).  In rodents, perinatal BPA exposure increased hepatic 
lipid content and lipogenic gene expression, along with imbalance in adipokine 
levels and insulin signaling disturbances in female offspring during 
adolescence and adulthood (15-17).  The mechanisms by which BPA induces 
fat accumulation are largely undescribed, but likely involve induction of 
lipogenesis through both direct (6) and epigenetic mechanisms (18). 
Epigenetic mechanisms, such as DNA methylation and histone modifications 
contribute to NAFLD (19-21).  DNA methylation patterns and lipogenic gene 
expression has been correlated in liver biopsy tissues from NAFLD patients 
(22).  Induction of fatty liver via a high-fat, high-sucrose diet was associated 
with hypomethylation at some CpG sites and increased transcripts for 
lipogenic proteins, such as sterol regulatory element binding protein 1c 
(Srebp-1c) and glycerol-3-phosphate dehydrogenase (Gpat) (23).  Similarly, 
hypomethylation at specific CpG sites of the Fatty acid synthase (Fas) 
promoter was induced by short-term or long-term high fat diet feeding and 
correlated with up-regulation of Fas expression (24, 25).  The mechanism by 
which induction of Srebp1-c in rodents with early-life exposure to BPA has not 
been elucidated, and it is hypothesized that it could also occur through 
promoter hypomethylation (7).  
Nuclear factor E2 related factor 2 (Nrf2) functions primarily as an antioxidant 
defense system of the cell.  Recently, Nrf2 has been linked to adipose 
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differentiation and lipid homeostasis- reviewed by (26).  Our previous work 
suggests positive regulation of Nrf2 on hepatic lipid accumulation.  In leptin-
deficient ob/ob mice, constitutive activation of Nrf2, by means of Keap1 
knockdown, enhanced hepatic steatosis (27).  Also, hepatic lipid deposition 
and glucose tolerance  worsened in Keap1 knockdown mice subjected to long-
term high fat diet challenge (28).  In rodent preadipocyte experiments, Nrf2 
transcriptionally regulated Ppar-γ and Cebp-β to enhance adipocyte 
differentiation and consequently lipid synthesis (29, 30). 
Here, we studied how early life exposure to BPA through perinatal and 
peripubertal exposure exerts epigenetic modifications in mice, and whether the 
modifications persist into adulthood.  First, it was hypothesized that PNPP 
BPA exposure induces hypomethylation of CpG sites in promoters of lipogenic 
genes (e.g. Srebp-1c and Fas) early in development, which would persist into 
adulthood.  Second, it was also determined whether Nrf2 expression increases 
with BPA exposure, and whether it can be correlated with promoter 
methylation status.  Overall, our findings herein confirmed that PNPP BPA 
exposure increases the expression of lipogenic enzymes in conjunction with 
hypomethylation at CpG sites in the promoter regions.  Moreover, we 
described increased Nrf2 recruitment to the Srebp-1c promoter in livers of 
BPA exposed mice. 
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2.3 MATERIALS AND METHODS 
2.3.1 Animals and dosing. CD-1 female mice (10-12 weeks of age) and 
proven breeder male mice  (Charles River Laboratories, Wilmington, MA) were 
maintained in temperature- and light-controlled (14/10-hr light/dark cycle) 
conditions at the at Tufts University Human Nutrition and Research Center 
animal facility (approved by the Association for Assessment and Accreditation 
of Laboratory Animal Care International).  All experimental procedures were 
approved by the Tufts University New England Medical Center Institutional 
Animal Care and Use Committee.  Cages, water, and bedding all tested 
negligible for estrogenicity.  Water was supplied ad libitum from glass bottles. 
Food (Teklad 2018; Harlan, Indianapolis, IN) was supplied ad libitum. The 
estrogenicity of food lots used was measured and found to be negligible (<20 
pmol estrogen equivalents per gram of feed).  Mice were paired to mate and 
breed. The day on which a vaginal plug was detected, considered gestational 
day 1 (GD 1). On GD 8, dams were implanted subcutaneously with Alzet 
osmotic pumps (model 1004; Alza Corp., Palo Alto, CA) following the 
manufacturer recommendations. Pumps were designed to deliver vehicle 
alone (50% DMSO in water) and BPA (25 µg/kg bw/day).  Care was taken to 
limit BPA contamination through housing or feeding.  These exposures to 
dams were continued until weaning age of pups, which is postnatal day 21 
(PND 21) and pups exposed to BPA through lactation.  After weaning age, 
exposure of BPA to pups continued through drinking water until PND 32 (week 
5).  Livers and serum were collected from female pups at week 5 and at week 
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39 and stored at -80°C until analysis (n=10 or 5/ group for week 5 and week 
39 respectively).  
2.3.2 Triglyceride quantification.  Total lipids were extracted from liver tissue 
by method previously described (28).  Briefly, liver tissue (50mg) was 
homogenized in 1 ml of phosphate buffer saline (PBS) and extracted with 
chloroform-methanol mixture (2:1).  Lipid extracts were vacuum-dried by using 
a Speedvac (Thermo Scientific) at 45°C.  The lipid residue was re-suspended 
in 1% Triton X-100 in 100% ethanol.  Triglyceride quantification was performed 
using a commercially available kit from Pointe Scientific Inc. (Canton, MI).   
2.3.3 Oil Red O staining.  About 5 μM thick sections were cut from frozen 
liver tissue using Vibratome UltraPro 5000 Cryostat (GMI, Ramsey, MN, USA).  
After acclimating to room temperature, the sections were fixed with 10% 
buffered formalin for 10 min and then stained with Oil red O (ORO) working 
solution. ORO stock solution was 0.5% Oil Red O in isopropanol.  A fresh 
working solution was prepared by combining 3 parts of stock solution with 2 
parts of deionized water.  Tissue sections were incubated in the working 
solution for 15 min at room temperature, the ORO solution was removed, and 
sections were quickly rinsed 2 times with fresh 60% isopropanol. Sections 
were next counterstained with hematoxylin, washed to water, and mounted in 
glycerin jelly.  
2.3.4 RNA isolation and quantitative real time PCR. Total RNA was isolated 
using TRIzol reagent (Invitrogen, CA) according to the manufacturer’s 
instruction.  RNA concentrations were determined by using spectrophotometer 
(Nanodrop ND1000, ThermoFischer Scientific, Waltham, MA, USA).  2μg of 
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RNA was converted to single stranded cDNA using a High-Capacity cDNA 
Reverse Transcription Kit (Invitrogen, Grand Island, NY).  Expression of genes 
at mRNA level were measured with quantitative real-time PCR using Light-
Cycler® 480 and SYBR Green (Roche Applied Science, Mannheim, Germany) 
detection system.  Levels of β2-microglobulin (B2M) used as reference 
housekeeping gene to normalize all data. Lipogenic target genes such as 
sterol regulatory element binding protein 1c (Srebp-1c), proliferator-activated 
receptor –gamma (Ppar–γ), acetyl CoA carboxylase-1 (Acc-1), fatty acid 
synthase (Fas) and glycerol 3 phosphate acyltrasferase (Gpat) and stearoyl 
CoA desaturase-1 (Scd)  were analyzed for mRNA expression and primers for 
all these genes are listed in Supplementary table S1.  
2.3.5 Determination of relative protein expression by western blot. 50mg 
of liver tissue was homogenized in 1ml of RIPA buffer using a Dounce 
homogenizer. The lysate was centrifuged a 12,000 rpm for 15 min at 4°C and 
the resulting supernatant was collected as a total protein extract.  Nuclear 
proteins were extracted from liver tissue using a NE-PER® kit (Thermo 
Scientific, Rockford, IL) and according to manufacturer's protocol.  The extract 
was quantified for protein content by a DC Lowry assay (Bio-Rad, Hercules, 
CA). 30 μg of protein/well was resolved by SDS-polyacrylamide gel 
electrophoresis and then proteins were transferred on PVDF membrane 
(Millipore Corporation, Billerica, MA) at 100 V for 45 min.  Membranes were 
blocked with 5% non-fat dry milk in tris-buffered saline with 0.1% tween-20 
(TBS-T). The membranes were then incubated overnight with primary antibody 
diluted in 2% milk in TBS-T.  Following washing with TBS-T, the membranes 
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were incubated with species-specific peroxidase-labeled secondary antibody 
(1:5000) in TBS-T for 1 hour at room temperature.  Next, membranes were 
washed in TBS-T, incubated in ECL+ (GE Healthcare, Waukesha, WI, USA).  
The resulting protein bands were visualized by autoradiography films, which 
were quantified using Quantity One software (Biorad, Hercules, CA). Specific 
information about the source, dilution, type, and molecular weight of primary 
and secondary antibodies is detailed in Supplementary Table S2.   
2.3.6 Chromatin Immunoprecipitation (ChIP) assay. Chip assays using liver 
tissues were performed according to the Active Motif ChIP-IT express kit 
protocol with modifications (Active Motif, Carlsbad, CA).  Briefly, 100 mg of 
liver tissue was homogenized with 4 ml of phosphate-buffered saline 
containing protease inhibitor.  Homogenate was cross-linked by adding 1% 
formaldehyde for 10 min and crosslinking was stopped by 125 mM glycine 
solution.  After washing twice with ice-cold PBS containing protease inhibitor 
followed by centrifugation, the pellet was suspended in SDS-lysis buffer for 40 
min on ice.  Dounce homogenizer was used to release nuclei from cells.  
Lysates were sonicated using a Branson Sonifier 250 (Branson Ultrasonics 
Corporation, Danbury, CT) 3 times with 12 seconds per stroke and a 1 min 
rest in between.  Cell debris was removed by centrifugation for 10 min at 
12,000 g at 4°C.  Shearing efficiency was optimized to obtain chromatin 
fragments between 200-800 bp and determined by 2% agarose gel 
electrophoresis.  A portion of sheared chromatin was used to determine the 
DNA concentration and equal amount of sheared chromatin (equivalent to 15 
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µg of DNA) was incubated with ChIP validated rabbit anti-Nrf2 antibody (C-20, 
sc-722x, Santa Cruz Biotechnologies, Dallas, TX) or anti-rabbit IgG antibody 
(Cell Signaling, Danvers, MA) overnight at 4°C with rotation.  A portion of 
sheared chromatin was preserved as input (10 µl).  Antibody-chromatin 
complex was recovered by adding pre-blocked Dynabeads Protein A (Life 
Tech, Grand Island, NY).  Using magnetic racks, beads were pelleted and 
sequentially washed.  Antibody and beads bound to chromatin were eluted by 
adding reverse crosslinking buffer and elution buffer sequentially.  DNA was 
purified by adding proteinase K and via phenol: chloroform: isoamyl alcohol 
extraction. DNA fragments were analyzed by end-point PCR or real time PCR 
using different primers that cover putative antioxidant response element (ARE) 
sequences on mouse Srebp-1c, Fas, and Acc promoters (Supplementary table 
S3).  Promoter sequences were identified using UCSC genome browser.  
Results are represented as agarose gel scans (end-point PCR) as well as fold 
enrichment (qPCR). 
2.3.7 Methylation analysis: 
A. Methylated DNA immunoprecipitation (MeDIP):  MeDIP assays were 
performed as described previously by (31).  Briefly, 6μg of genomic DNA was 
sheared by series of 3×20 pulses of sonication using Branson Sonifier 250 at 
power level 2 on the machine.  Sonication efficiency was checked by agarose 
gel electrophoresis and fragment size of DNA was verified approximately 500 
kb.  350 μl of TE buffer was added to sonicated DNA and denatured at 95°C 
for 10 min and then immediately placed on ice for 5 min. Sonicated and 
denatured DNA was diluted with 100 μl of 5X IP buffer (50 mM Na-phosphate 
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pH7, 700 mM NaCl, 0.25% Triton X-100) and incubated with 5μg of 5-
methylcytosine monoclonal antibody (5-mc) (Epigentek Group Inc, 
Farmingdale, NY) and with anti-rabbit IgG antibody (Cell Signaling, location) 
overnight at 4°C with rotation.  Protein A/G beads were prewashed with 0.1% 
PBS-BSA and resuspended in 40 μl of 1X IP buffer. Beads were added to 
DNA-Antibody complex and incubate for 2 hrs at 4°C on rotating platform.  
Beads-DNA- antibody complex were washed three times with 1X IP buffer and 
after washing complex were re-suspended in 250 μl of digestion buffer (50 mM 
Tris HCl pH 8, 10 mM EDTA, 0.5%SDS) containing 3.5 μl of proteinase-k 
(Sigma Aldrich, St. Louis, MO, USA) and then incubated at 55°C on a rotating 
platform.  DNA purification was performed by phenol: chloroform: isoamyl 
alcohol extraction, and resuspended in 30 μl of TE buffer.  Methylated 
enriched DNA was amplified by real time PCR by using different primers that 
covers CpG sites of promoter of Srebp-1c, Fas, and Nrf2 (Supplementary 
table S4).  Methylation status of these promoters was plotted in the form of 
fold enrichment.   
B. Pyrosequencing: DNA methylation quantitation of CpG sites was 
performed by Pyrosequencing technology using PyroMark MD (Qiagen, Santa 
Clarita CA). Firstly, Pyrosequencing assays for interest region of Nrf2 
promoter were designed with PyroMark Assay Design Software version 2.0. 
DNeasy Blood & Tissue Kit (Qiagen, Santa Clarita CA, catalog number: 
69504) was used to isolate total genomic from frozen liver tissues and DNA 
concentrations were determined by using spectrophotometer (Nanodrop 
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ND1000, ThermoFischer Scientific, Waltham, MA, USA). Genomic DNA was 
bisulfide converted by using EZ DNA Methylation™ Kit (Zymo Research, 
Irvine, CA, catalog number: D5001). Briefly, sodium bisulfite was added to 
approximately 1 μg of genomic DNA, converting unmethylated cytosines to 
uracil, which are replaced with thymine during PCR; methylated cytosines 
remain unchanged.  After bisulfite conversion, amplification of Nrf2 gene 
regions of interest was performed using PyroMark PCR Kit (Qiagen, Santa 
Clarita CA), forward primer (50 pmol), and biotinylated reverse primer (50 
pmol) in a 25 μl PCR reaction system.  The PCR conditions, forward, reverse 
and sequencing primers and biotin labeling for all assays are shown in table 2. 
The PyroMark MD Pyrosequencer platform (Qiagen) was utilized according to 
manufacturer suggested protocol to quantify DNA methylation at the selected 
CpG sites (computed by Pyro Q-CpG Software). Percent DNA methylation 
calculated by standard curve by quantifying methylation of commercially 
available 0% and 100% methylated control DNA (80-8060M-PreMix Mouse 
Methylation Controls- Premix Set, EpigenDx Inc, Hopkinton MA) on each 96-
well plate.  
2.3.8 Cell culture and transient transfection reporter gene assay: 
Human Srebp1c promoter of 1565 bp corresponding to the 5′ upstream region 
cloned in pGL3-basic luciferase vector was graciously donated by Dr. Marta 
Casado (Instituto de Biomedicina de Valencia, Valencia, Spain).  Expression 
plasmid p3XFLAG-myc-CMV-26 (EV26) was obtained from Sigma-Aldrich (St 
Louis, MO).  NRF2 ORF cloned into EV26 was graciously donated by Dr. Jose 
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Manautou (University of Connecticut, Storrs, CT).  HepG2 cells were cultured 
in DMEM containing 25mM glucose, 10% fetal bovine serum, 1% penicillin-
streptomycin (10,000 U/mL) and 1% non- essential amino acid (NEAA) under 
the humidified atmosphere of 95% air to 5 %CO2 at 37°C.  Co-transfections 
(Srebp1c luciferase reporter constructs and transcription factor expression 
plasmids) were performed using Lipofectamine 3000 (Life Technologies, 
Tarrytown NY) according to the manufacturer’s manual.  For all transfections, 
plasmid DNA used per well were 75ng for Srebp promoter construct, 15ng of 
Nrf2 expression plasmid and 10ng null renilla luciferase (pRL-CMV) as internal 
control.  After 24 hrs of transfection, cells were lysed by 1× passive lysis buffer 
and preceded for luciferase activity.  For Nrf2 activator treatment experiments, 
after 24 hrs of Sreb1c luc promoter plasmid transfection, cell were treated with 
oleanolic acid (50uM) and sulforaphane (10uM) in 0.05% DMSO 12hrs.  After 
treatment, cells were lysed with 1× passive lysis buffer and luciferase activity 
was measured relative firefly/renilla luciferase Dual-Luciferase® Reporter 
Assay System (Promega, Madison, CA) with GloMaxTM Luminometer 
(Promega, Madison, CA) according to manufacturer’s protocol. 
2.3.9 Statistical Analysis. Control and treated groups were analyzed by 
Student’s t-test.  Asterisk * indicates statistically significant difference between 
the control and BPA treated group (p<0.05).   
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2.4 RESULTS 
2.4.1 Effects of perinatal peripubertal bisphenol A (PNPP BPA) exposure 
on body weight, liver weight and hepatic lipid accumulation. Prior to 
present study, pilot study on PNPP BPA exposure was performed in both male 
and female offspring.  Initial data obtained from male mice did not indicate any 
increase in liver triglycerides or lipogenic gene expression at week 39 
(Supplementary figure S1), but treatment related differences were present in 
tissues from female mice.  Based on these results, female mice were chosen 
for further study.  Pilot dose finding studies indicated that free BPA in serum in 
the dams and pups at PND 32 was below detectable limits.  Detectable levels 
of total BPA in serum of mothers and pups was 0.6-0.7 ng/ml for BPA 25.  
Fig. 1A shows changes in body and liver weight between control and BPA 
treated animals.  BPA increased body weight by ~15% compared to control at 
both ages.  Liver weights were similar between treatment groups at both ages.  
As compared to control, BPA significantly increase hepatic TG content at week 
5 by about 33%, but not significant increase in week 39 (Fig.1B).  ORO 
staining of frozen sections revealed more lipid accumulation with BPA in both 
week 5 and week 39 livers as compared to respective controls.  
Representative images are presented in fig.1C, and three images from each 
sample in all the groups were used to quantify lipid deposits and plotted (Fig. 
1D) 
2.4.2 Effect of PNPP BPA exposure on expression hepatic lipogenic gene 
expression in female mice at puberty (week 5) and adult (week 39) age. 
The effect of PNPP BPA exposure on gene expression related to hepatic lipid 
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metabolism was evaluated by real time PCR.  Fig. 2 illustrates the effect of 
PNPP BPA exposure on expression of transcription factors (Srebp1, Ppar-γ) 
involved in regulation of hepatic lipid homeostasis as well as key enzymes 
Acc, Fas and Gpat at both puberty as well as adult age of female offspring.  At 
week 5, except Scd, BPA induced increase in other targets measured was not 
significant.  However, at week 39, Ppar-γ, Fas, Acc, and Gpat mRNA 
expression was approximately doubled compared to controls (Fig. 2A, 2B). 
Figures 3 and 4 depict expression of proteins in liver related to hepatic lipid 
accumulation in both weeks with BPA exposure.  In week 5 females, BPA 
increased Ppar-γ levels in nuclear fractions by 300% compared to controls.  
BPA increased pSrebp1 protein levels to two-fold compared to controls.  At 
week 39, significant induction in protein expression of Ppar-γ and Srebp1c 
was noted (Fig 3A, 3B).  At week 5, BPA increased Fas, Acc, and pAcc protein 
expression by more than 135%, 200% and 135% respectively.  At week 39, 
BPA25 increased Fas and pAcc protein expression by 50 and 75%, but did not 
significantly increase Acc levels (Fig. 4A, 4B).   
2.4.3 PNPP BPA exposure enhanced Nrf2 and Nrf2-dependent protein 
expression. Messenger RNA and protein expression for Nrf2, and its target 
enzymes Gclc were determined (Fig. 5).  Protein expression of nuclear Nrf2 
and total Gclc were increased by 30% or more with BPA treatment in both 
week 5 and week 39 livers.     
To examine whether BPA exposure was associated with increased oxidative 
stress, reduced GSH was measured in liver.  At week 39, hepatic GSH 
concentration was similar between controls and BPA exposed group 
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(Supplementary figure S2), indicating a lack of significant oxidative stress in 
liver. 
2.4.4 PNPP BPA exposure was associated with hypomethylation in 
regions of the mouse Srepb-1c and Nrf2 promoters.  The effect of BPA on 
gene-specific promoter methylation was determined using methylated DNA 
immunoprecipitation (MeDIP) using 5- methyl cytosine antibody (5-MC) and 
according to published protocol (31).  Promoter sequences for lipogenic 
targets were analyzed for presence of CpG site on Methprimer (University of 
California, San Francisco), and these sites were checked for methylation 
status.  In week 5 mice, BPA decreased methylation in regions upstream of 
the translational start site.  BPA treated groups showed less enrichment of 5-
MC for Srebp1-c promoter (-231 to -346 and -1325 to -1456), Fas promoter (-
306 to -472 and -654 to -832) and at one promoter region checked for Nrf2 (-
1059 to -1168) (Fig. 6).  In week 39 livers, BPA was associated with markedly 
less enrichment of methylated DNA at multiple regions.  With exception of 
Srebp-1c promoter region from -231 to -346, other promoter regions checked 
displayed a uniform decrease in the DNA methylation.  
Further, a sequence of Nrf2 promoter (-1405 to -1088) containing 4 CpG sites 
(CpG#1, 2, 3 and 4 respectively at -1132, -1144, -1147, -1157) was analyzed 
to determine change in site-specific methylation upon BPA exposure by 
pyrosequencing using bisulfide converted DNA (Table 1).  In week 5, CpG#1 
site is significantly less methylated in BPA treated mice as compared to 
control.  No change in three other CpG sites was observed.  Interestingly, in 
week 39, BPA significantly lower percent methylation of other CpG site 
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(CpG#4).  Multiple other regions of the Srebp-1 and Nrf2 promoter were also 
checked, and displayed no prominent changes in DNA methylation with BPA 
in week 5 and week 39 mice (Data not shown). 
2.4.5 PNPP BPA exposure enhances recruitment of Nrf2 to the promoter 
of lipogenic genes. In week 5 mice, BPA increased recruitment of Nrf2 to a 
putative ARE binding site at -120 to -130 upstream of translational start site in 
mouse Srebp-1c gene as compared to negative control (IgG) depicted 
transcriptional regulation of Srebp-1c by Nrf2 upon BPA treatment.  
Interestingly, this transcriptional regulation of lipogenic proteins by Nrf2 was 
persistent with BPA in week 39 mice as well (Fig 7B).  BPA exhibited higher 
binding of Nrf2 on Srebp-1c, at same region of upstream of translation start 
site in week 39 females.  Real time PCR results also showed higher 
enrichment of Nrf2 on Srebp-1c promoter upon BPA treatment in both week 5 
and week 39 mice (Fig 7C).     
2.4.6 Effect of NRF2 Over-expression on transactivation of human Srebp-
1c promoter. Co-transfection of reporter genes with NRF2 increased 
luciferase activity and thus significantly transactivated Srebp1c reporter 
(Figure 8A) indicating the potential ARE is located in this Srebp1 promoter 
region.  Furthermore, treatment of HepG2 cells with known Nrf2 activators, 
sulforaphane and oleanolic acid, enhanced transactivation of the Srebp-1c 
promoter, supporting the presence of functional ARE in Srebp-1c promoter.  
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2.5 DISCUSSION 
Using BPA as a model compound, here we provide a first evidence for Nrf2-
mediated environmental chemical induced lipid homeostasis alterations.  
Presence of functional ARE in the Srebp-1c promoter demonstrates 
involvement of Nrf2 in hepatic lipid accumulation under the influence of 
chemical exposure.  Moreover, persistent effects of BPA induced steatosis 
pertinent of DNA hypomethylation are in agreement with published literature 
that demonstrates epigenetic imprinting capabilities of BPA –reviewed by (32).   
We report induction of hepatic steatosis with PNPP BPA exposure in young 
and adult female mice.  Our findings are consistent with a recent pediatric 
study, which demonstrated higher levels of urinary BPA in females as 
compared to males, with an association with NAFLD (13).  Moreover, in 
human cross-sectional studies, urinary BPA levels correlated positively with 
BMI more significantly in girls between 9 to 12 years of age than other age 
groups, implying the sensitivity of pubertal female population to BPA (12).  The 
observed increased lipid level was associated with induction of mRNA and 
protein expression of enzymes and transcription factors that induce hepatic 
lipid accumulation. Furthermore, the findings herein have uncovered new 
mechanisms for PNPP BPA-induced hepatic steatosis through promoter 
hypomethylation, describing new areas of differential methylation at the Srebp-
1c, Fas, and Nrf2 mouse promoters, as well as describe Nrf2 enrichment at 
new putative AREs in the mouse Srebp-1c promoter.  
The Environmental Protection Agency and US Food and Drug Administration 
published tolerable daily intake (TDI) value for BPA around 50μg/kg, and the 
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exposure level chosen in current study is lower than TDI.  More importantly, 
published studies suggest that dose of 400μg/kg BW/day in mice resulted in 
serum levels (0.5ng/ml) of unconjugated BPA much lower than amount noted 
in human serum after environmental exposure (2 ng/ml) (33).  In addition to 
dose, timing of exposure to potential endocrine disruptors like BPA is also a 
critical determinant for disease susceptibility (6, 34).  Effects of fetal or 
neonatal exposure of BPA are hypothesized to be as critical as adult exposure 
(6, 35).   As based on ‘fetal plasticity’ theory any effects that affect embryo can 
remain persistent for life.  In our model, female mice were exposed to BPA 
during gestation and lactation.  Overall, it was observed in the study herein 
that BPA induced hypomethylation at some sites in the liver genome that 
persisted (e.g. Srebp1c -1325 to -1456; Fas -654 to -832, -306 to -472; Nrf2 -
1059 to -1168), whereas methylation in other sites in the genome differed at 
weeks 5 and 39.  This data suggests the potential that some sites might be 
persistently “marked”, whereas others are more “plastic” with the ability to be 
more dynamically regulated by methylation-regulating enzymes or changes in 
methyl donor content.  This observation is highly relevant to the field of 
epigenetics and supports other observations of plasticity in methylation (36).  
Effects at low dose, as well as exposure time dependent effects support the 
notion of BPA being a “critical window of exposure” compound. 
In the current study, as well as published findings (7), liver weights remained 
unchanged with BPA exposure irrespective of route and time of administration 
in both mice and rats.  Interestingly, BPA exposed rodents exhibited evident 
hepatic lipid accumulation among several studies (6, 7).  A major source of 
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liver lipids besides dietary consumption is de novo synthesis (37).  Our 
observations herein, as well as ones from the latter studies using rodents are 
supported to some degree by recent finding published associated NAFLD with 
BPA exposure in children (13).    The majority of BPA exposure studies related 
to NAFLD have focused primarily on disturbances lipid synthesis at the 
transcriptional level.  Induction of Srebp-1c and Ppar-γ in livers was observed 
across all these studies, and the resulting Fas and Acc induction could be a 
result of enhanced transcriptional regulation or direct action of BPA on these 
enzymes.  Impairment of E-oxidation can also result in lipid accumulation in 
liver (38).   In our study, down regulation of oxidation regulators in week 5 
animals on mRNA level was observed (Supplementary figure S3); however, 
effect did not remain consistent in adult animals.   Further exploration of BPA 
effect on lipid oxidation is needed. 
Early life exposure to BPA caused persistent changes in lipogenesis that were 
observed in adult even after stopping the exposure in current study.  In 
previous study, in utero and lactational exposure of BPA showed accumulation 
of lipid in adult rat liver by induction of Srebp-1c and related genes; however 
the study did not reveal the mechanism of lifelong effect of early exposure but 
they postulated the epigenetic regulation of lipogenic pathway (7).  In present 
study, PNPP exposure of BPA did changes at lipogenic as well as Nrf2 gene 
specific promoter methylation when analyzed by MedIP.  Potential of BPA to 
cause gene specific promoter methylation changes have also been studied in 
other genes involved in insulin signaling pathway which resulted in 
disturbances of adulthood glucose homeostasis (39).  BPA induced 
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hypomethylation was evident in week 5 as well as week 39 animals; however, 
extent of hypomethylation differed between ages.  These differences in age-
dependent methylation patterns need further investigation.  Gene and protein 
expression changes in adult age also appeared more prominent in adult mice 
as opposed to younger mice.  Less uniform epigenetic results, associated with 
less prominent changes in gene expression in week 5 animals suggest that 
biological effects exerted by early life BPA exposure of a major concern in 
adult population.  Moreover, lack of perfect correlation between DNA 
methylation changes and gene/ protein expression changes also imply 
possibility of involvement of other epigenetic mechanisms besides promoter 
methylation.   
BPA-mediated induction of lipid synthesis enzyme expression has been 
demonstrated (6), however the upstream mechanism by which BPA imparts 
this upregulation remains unknown.  One potential mechanism could be via 
upregulation of Nrf2 expression and regulation of lipogenic genes as 
previously described (28, 40).  Although most commonly studied for countering 
oxidative stress, Nrf2 can be upstream regulator of adipogenesis through 
Ppar-γ and Cebp-β transcriptional regulation in rodent pre-adipocytes (29, 30).  
Along with adipose tissue, the role of Nrf2 in regulation of hepatic lipid 
synthesis is an area under investigation.  Direct in vitro exposure of BPA in 
human embryonic kidney (HEK) cells induced nuclear level of Nrf2 (41).  
Similarly, present study depicted induction of Nrf2 expression at mRNA as well 
nuclear protein level upon PNPP exposure to BPA.  With the help of ChIP 
assay in our study we showed novel binding of Nrf2 on consensus ARE 
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sequence on Srebp-1c promoter.  Moreover, BPA exposure enhanced this 
binding and hence we can infer that BPA induced expression of Srebp-1c 
expression in our model is possibly mediated through Nrf2 regulation.  
Transfection of Nrf2 in HepG2 cells, as well as its activation by known 
chemicals oleanolic acid and sulforaphane demonstrated luciferase activity at 
the Srebp-1c promoter reporter.  These findings establish novel function for 
Nrf2 from transcriptional regulation of hepatic denovo lipogenesis.   
Overall, the present study provides the mechanistic exploration of exposure to 
environment toxicants like BPA for adulthood metabolic disorders like hepatic 
steatosis.  Because of persistent mechanisms such as epigenetic imprinting, 
exposure to environmental chemicals exerts biological effects not only based 
on amount, but on the time of exposure.  We addressed promoter methylation 
changes caused by PNPP BPA exposure, but certainly other epigenetic 
mechanisms need to be explored in detail as well, to obtain more 
comprehensive picture regarding these persistent effects.  Histone 
modifications or microRNA changes (42, 43) that are known to be affected in 
or known to cause NAFLD also need elucidation in regard to environmental 
toxicity.  Also, considering ubiquitous expression and function of Nrf2, its role 
in environmental toxicity is vital to study.  Here we provide evidence for 
binding of Nrf2 on promoters of lipogenic genes, and the binding increases 
with BPA exposure.  In conclusion, PNPP BPA induced lipogenic effects were 
demonstrated in this study, and detailed epigenetic and Nrf2-mediated 
mechanisms were elucidated.  
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2.6 FIGURE LEGENDS 
Figure 1: Perinatal peripubertal (PNPP) exposure to bisphenol A affects 
body weight and hepatic lipid accumulation in female CD1 mice.  A) Body 
weight and liver weight.  Statistical differences between the groups were 
determined by Student’s t-test.  Asterisk (*) represents significant difference in 
weights between BPA treated and vehicle treated animals of same age group 
(p≤0.05).  B) Hepatic triglyceride (TG) quantification. C) Oil red o (ORO) 
staining of lipids in the liver tissue.  Representative images are displayed in 
200X magnification. D) Quantification of oil red staining density from all the 
samples. 
Figure 2: Perinatal peripubertal (PNPP) exposure to bisphenol A 
increases mRNA expression of lipogenic targets in livers of female CD1 
mice (A. Week 5; B. Week 39). mRNA was quantified using real time 
polymerase chain reaction (RT-PCR) using primers specific for sterol 
regulatory element binding protein 1c (Srebp-1c), peroxisome proliferator 
activated receptor gamma (Ppar-γ), fatty acid synthase (Fas), acetyl coA 
carboxylase (Acc), and glycerol-3-phosphate acetyl transferase (Gpat).  Raw 
data was normalized to respective control expression, and statistical 
differences between the groups were analyzed by Student’s t-test.  Asterisk (*) 
represents significant difference in expression between BPA treated and 
control animals (p≤0.05). 
Figure 3: Perinatal peripubertal (PNPP) exposure to bisphenol A 
increases protein expression of lipogenic transcription factors in livers 
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of female CD1 mice (A. Week 5; B. Week 39). Nuclear proteins were 
detected for expression using specific antibodies for peroxisome proliferator 
activated receptor gamma (Ppar-J), sterol regulatory element binding protein 
1c (Srebp-1c), and phosphorylated Srebp-1c.  The blots were developed using 
autoradiography and the mean blot intensity is presented in percent protein 
expression format.  Statistical differences between the groups were analyzed 
by Student’s t-test.  Asterisk (*) represents significant difference in expression 
between BPA treated and control animals (p≤0.05). 
Figure 4: Perinatal peripubertal (PNPP) exposure to bisphenol A 
increases protein expression of lipid synthesis enzymes in livers of 
female CD1 mice (A. Week 5; B. Week 39). Protein expression was 
quantified by western blot using specific antibodies for fatty acid synthase 
(Fas), acetyl CoA carboxylase (Acc) and phosphorylated Acc.  The blots were 
developed using autoradiography and the mean blot intensity is presented in 
percent protein expression format.  Statistical differences between the groups 
were analyzed by Student’s t-test.  Asterisk (*) represents significant 
difference in expression between BPA treated and control animals (p≤0.05). 
Figure 5: Perinatal peripubertal (PNPP) exposure to bisphenol A and 
nuclear factor E2 related factor 2 (Nrf2) signaling in livers of female CD1 
mice.  A) Nrf2 and its target gene glutamate cysteine ligase (Gclc) expression 
in livers of week 5 animals. mRNA expression was quantified using real time 
polymerase chain reaction (RT-PCR) using primers specific for Nrf2 and Gclc.  
B) Protein expression of nuclear Nrf2 and Gclc.  Protein expression was 
quantified by western blot using specific antibodies for Nrf2 and glutamate 
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cysteine ligase (Gclc).  The blots were developed using autoradiography and 
the mean blot intensity is presented in percent protein expression format. C) 
Nrf2 and Gclc mRNA expression in week 39 animals.  D) Protein expression of 
nuclear Nrf2 and Gclc in week 39 animals.  Statistical differences between the 
groups were analyzed by Student’s t-test.  Asterisk (*) represents significant 
difference in expression between BPA treated and control animals (p≤0.05).   
Figure 6: Effect of Perinatal peripubertal exposure of BPA on promoter 
methylation of Srebp-1c, Fas and Nrf2 analyzed by methylated DNA 
immunoprecipitation (MeDIP). Genomic DNA (6μg) was sonicated, 
denatured and subjected to immunoprecipitation by using 5-methyl cytosine or 
IgG antibody.  Agarose beads were used to recover enriched methylated DNA.  
After purification real time PCR were performed to amplify methylated DNA 
fragments using different primers covering promoter sequences containing 
CpG sites.  CpG sites in Promoter sequences of Srebp-1c, Fas and Nrf2 (A, B 
and C respectively) up to 2 kb upstream of translational start site were 
analyzed to check methylation effects of PNPP BPA.  Results are plotted in 
the form of fold enrichment. 
Figure 7: Chromatin immunoprecipitation of nuclear factor E2 related 
factor 2 (Nrf2) on Srebp-1c gene promoter. A. Nrf2 recruitment on promoter 
of Srebp-1c (Schematic representation). Liver tissues of BPA treated both 
young as well as adult female offsprings mice were homogenized with PBS. 
Homogenate was cross-linked by adding 1% formaldehyde for 10 min and 
crosslinking was stopped by 125 mM glycine solution.  Crosslinked chromatin 
was sheared and immunoprecipitated with anti-Nrf2 or anti-rabbit IgG antibody 
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overnight at 4°C with rotation. Antibody-chromatin complex was recovered by 
adding preblocked Dynabeads Protein A.  After reverse crosslinking and 
purification Nrf2 and IgG precipitated DNA were subjected to B. End point 
PCR, C. Real time PCR amplification by using primers as enlisted in 
supplementary table S3, which covers putative ARE consensus sequence on 
promoter of Srebp-1c.  Results are plotted in the form of fold enrichment 
compared to negative control.   
Figure 8:  Nrf2 mediated transactivation of human Srebp-1 in vitro. A. 
Transcription factor NRF2 expression plasmid were transiently co-transfected 
with the Srebp-1 promoter luciferase reporter constructs (-1.5kb) or pGL3 
basic, in HepG2 cells for 24hrs in serum free DMEM media. Luciferase activity 
was measured as relative firefly/renilla luciferase and was recorded as relative 
light units data are presented as mean fold change ± SEM.  Statistical 
differences between the groups were analyzed by one-way ANOVA followed 
by Duncan’s posthoc test.  Asterisk (*) represents significant difference in 
expression between BPA treated and control animals (p≤0.05).  B. Effect of 
Nrf2 activators on Srebp-1c directed reporter gene activity:  Srebp-1c promoter 
luciferase reporter constructs or pGL3 basic were transiently transfected into 
HepG2 cell. After 24 hrs of transfection HepG2 cell were treated with the 
oleanolic acid (50uM) and sulforaphane (10uM) along with DMSO (0.05%) for 
12hrs.  Luciferase activity was measured using a commercial kit.  
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2.9 TABLES: 
Table 1: Site specific methylation (%) of 4 CpG sites for Nrf2 promoter 
upon PNPP BPA exposure in week 5 and 39 age of mice.  Values were 
adjusted to a standard curve of control DNA (ranging between 0 and 100%) 
run for each CpG site on the corresponding experimental plate for each 
sample.  Asterisk * represents statistically significant difference between 
control and BPA treated groups (p<0.05). 
 
 
Week 5 CpG #1 CpG #2 CpG #3 CpG #4 
Control 20.47 ± 2.44 7.46 ± 1.62 2.39 ± 0.90 8.16 ± 1.88 
BPA 11.61 ± 1.74* 6.52 ± 1.47 5.16 ± 2.24 10.84 ± 2.67 
Week 39 CpG #1 CpG #2 CpG #3 CpG #4 
Control 13.26 ± 0.61 6.44 ± 1.23 4.38 ± 1.74 19.03 ± 0.9 
BPA 15.70 ± 3.30 6.49 ± 0.95 2.44 ± 1.26 7.64 ± 2.42* 
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Table 2: PCR conditions for Pyro-Sequencing  
Primer/sequence to analyze Nrf2 Assay 
Forward PCR primer GTAGTTAAAGAAGTATGTTTGGGAATGA 
Reverse PCR primer Biotin-TATAATCTCATAAAACCCCACCTCTC 
Sequencing primer (5’ to 3’) ATAATAAGAATTATATTAAAGGG 
Amplicon length 318 
Temperature 58 
Number of cycles 45 
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2.12 SUPPLEMENTARY DATA: 
Supplementary figure S1: Effect of perinatal peripubertal (PNPP) BPA 
exposure on hepatic triglyceride (TG) and mRNA expression in male 
offsprings at week 39 of age. A. TG quantification.  B. Gene expression of 
lipogenic targets. Raw data was normalized to respective control expression, 
and statistical differences between the groups were analyzed by Student’s t-
test.  Asterisk (*) represents significant difference in expression between BPA 
treated and control animals (p≤0.05). 
Supplementary figure S2: Glutathione (GSH) levels in the livers of week 
39 mice exposed to PNPP BPA. Liver tissue was homogenized and the GSH 
was quantified by commercial kit from Promega (Madison, WI).  Raw data was 
normalized to respective control expression, and statistical differences 
between the groups were analyzed by Student’s t-test.   
Supplementary figure S3: Perinatal peripubertal (PNPP) exposure to 
bisphenol A increases mRNA expression of E-oxidation targets in livers 
of female CD1 mice (A. Week 5; B. Week 39).  Total RNA was extracted 
from liver tissue by phenol-chloroform extraction using TRIzol® reagent.  
Messenger RNA was converted to cDNA and subsequently quantified using 
real time polymerase chain reaction (RT-PCR) using primers specific for 
peroxisome proliferator activated receptor alpha (Ppar-α), cytochrome P450 
4a10 (Cyp4a10), carnitine palmitoyltransferase 1a (Cpt1a). Raw data was 
normalized to respective control expression, and statistical differences 
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between the groups were analyzed by Student’s t-test.  Asterisk (*) represents 
significant difference in expression between BPA treated and control animals 
(p≤0.05). 
Supplementary table S1: Primer sequence for quantitative RT-PCR 
Supplementary table S2: List of primary and secondary antibodies for 
western blot and chromatin immunoprecipitation 
Supplementary table S3: Primer sequence for amplification of DNA from 
chromatin immunoprecipitation 
Supplementary table S4: Primer sequence for Methylated DNA 
immunoprecipitation output amplification 
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Supplementary table S1: Primer sequence for quantitative RT-PCR 
 
   
Gene Forward Reverse 
Srebp1c GCAGCCACCATCTAGCCTG CAGCAGTGAGTCTGCCTTGAT 
Ppar-γ CTCTGTTTTATGCTGTTATGGGTGA GGTCAACAGGAGAATCTCCCAG 
Fas GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG 
Acc GATGAACCATCTCCGTTGGC GACCCAATTATGAATCGGGAGTG 
Gpat ACAGTTGGCACAATAGACGTTT CCTTCCATTTCAGTGTTGCAGA 
Nrf2 TCTTGGAGTAAGTCGAGAAGTGT GTTGAAACTGAGCGAAAAAGGC 
Keap1 CTGCCCAATTCATGGCTCACA CTTAGGGTGGATGCCTTCGAT 
Nqo1 AGGATGGGAGGTACTCGAATC TGCTAGAGATGACTCGGAAGG 
Gclc GGGGTGACGAGGTGGAGTA GTTGGGGTTTGTCCTCTCCC 
B2M TTCTGGTGCTTGTCTCACTGA CAGTATGTTCGGCTTCCCATTC 
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Supplementary table S2: List of primary and secondary antibodies for 
western blot and chromatin immunoprecipitation assay
Antibody 
name 
Primary/ 
Secondary 
Protein 
fraction Application Source 
Gapdh/ B-
actin Primary 
Total, 
Membrane WB 
Cell Signaling 
Tech 
Acc-1 Primary Total WB 
Cell Signaling 
Tech 
 
pAcc-1 Primary Total WB 
Cell Signaling 
Tech 
 
Ppar-γ Primary Total WB 
Cell Signaling 
Tech 
 
Srebp1c 
Primary Total WB Active Motif  
  ChIP Active Motif  
p-Srebp1c  Total WB 
Cell Signaling 
Tech 
 
Nrf2 
Primary Nuclear WB Gift from Dr. Schmidt’s lab 
  ChIP 
Cell Signaling 
Tech 
 
Gclc Primary Total WB Abcam 
Anti-mouse Secondary - WB Sigma Aldrich 
Anti-rat Secondary - WB Sigma Aldrich, St Louis, MO 
Anti-rabbit Secondary - WB Sigma Aldrich, St Louis, MO 
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Supplementary table S3: Primer sequence for ChIP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Promoter 
Predicted ARE 
(Considering 
Coding start site 
as +1) 
Forward Reverse 
Srebp 1c 
 
-120 to -130 
 
 
TAGGCGAGCTGTCAGGAT 
 
 
TCTCGGCCAGTGTCTGT 
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3.1 ABSTRACT: 
PFOS is a chemical of nearly ubiquitous exposure in humans.  Recent 
studies have associated PFOS exposure to adipose tissue-related effects.  
The present study was to determine whether PFOS alters the process of 
adipogenesis in mouse and human preadipocytes and regulates insulin-
stimulated glucose uptake.  In murine-derived 3T3-L1 preadipocytes, PFOS 
enhanced hormone-induced differentiation to adipocytes and adipogenic 
gene expression, increased insulin-stimulated glucose uptake at 
concentrations ranging from 10 to 100 PM, and enhanced Glut4 and Insulin 
receptor substrate-1 expression.  Nrf2, Nqo1 and Gclc were significantly 
induced in 3T3-L1 cells treated with PFOS, along with a robust induction of 
antioxidant response element (ARE) reporter in mouse embryonic 
fibroblasts isolated from ARE-hPAP transgenic mice by PFOS treatment.  
Chromatin immunoprecipitation assays further illustrated that PFOS 
increased Nrf2 binding to ARE sites in mouse Nqo1 promoter, suggesting 
that PFOS activated Nrf2 signaling in murine-derived preadipocytes.  
Additionally, PFOS administration in mice (0.1mg/kg BW/day) induced 
adipogenic gene expression and activated Nrf2 signaling in epididymal 
white adipose tissue.  Moreover, human visceral preadipocytes illustrated 
that PFOS (5 and 50 PM) promoted adipogenesis and increased cellular 
lipid accumulation.  It was observed that PFOS increased Nrf2 binding to 
ARE sites in association with Nrf2 signaling activation, induction of Ppar-J 
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and Cebpα expression, and increased adipogenesis.  This study points to a 
potential role PFOS in dysregulation of adipose tissue expandability, and 
warrants further investigations on the adverse effects of persistent 
pollutants on human health. 
 
Key words: PFOS, Nrf2, Ppar-J, adipogenesis, glucose uptake, ARE 
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3.2 INTRODUCTION 
Perfluorooctanesulfonate (PFOS) and Perfluorooctanoic acid (PFOA) are 
organic fluoroalkyl chemicals widely used in industrial and consumer 
applications as powerful surfactants and building material components, as 
they are stable at high temperature and nonflammable (Olsen et al., 2005).  
These two chemicals have been detected worldwide in the environment, 
including drinking water (Skutlarek et al., 2006), atmosphere air (Shoeib et 
al., 2005), soil, sediments (Boulanger et al., 2005), and even the wildlife in 
the Antarctic Pole (Giesy and Kannan, 2001).  Average human serum 
PFOS and PFOA content has decreased between 2000 and 2005 due to 
the phase out of perfluorooctanesulfonyl-fluoride (POSF, C8F17SO2F)-
based materials by the primary global manufacturer, 3M Company, in May 
2000 (Olsen et al., 2007b), but the related health effects still remain a 
concern.  Although have been banned in United States and Europe, PFOS 
and PFOS-related chemicals are still currently produced in China. 
Importantly, PFOS and PFOA are readily absorbed and poorly eliminated 
from humans.  Increased renal absorption via transport mechanisms is 
suspected to be the mechanism that contributes to the relatively long 
serum half-lives observed in humans (Olsen et al., 2007a), which has been 
estimated to 5.4 (PFOS) and 3.8 (PFOA) years.  Because of its persistence 
in the body and presence in populations across the world, it is important to 
assess potential health effects.  Liver is the major organ affected by 
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exposure of PFOS in animal model, as it is known to deposit in liver and is 
associated with increased liver weight in rats, mice, and monkeys (Chang 
et al., 2012; Wan et al., 2012).  Exposure of PFOS has been shown to 
induce further undesirable effects, such as increased hepatic lipid 
accumulation along with significant induction of CD36 and lipoprotein lipase 
(Lpl) expression, which resulted in disturbance of lipid metabolism and 
excessive fatty liver (Wan et al., 2012).  In addition, dietary administration 
of PFOS in mice (0.005%, w/w) for 10 days reduced serum cholesterol and 
triglycerides levels, and induced a moderate hepatomegaly (Qazi et al., 
2010).  More recent publications reported that exposure of PFOS altered 
expression of genes mainly involved in lipid modulation, energy metabolism, 
reproduction, hormone regulation, suggesting a role for PFOS in regulating 
lipid metabolism and development (Hu et al., 2005; Hagenaars et al., 2008).  
The observed hepatomegaly that results from PFOS administration is due 
to peroxisome proliferator-activated receptor (Ppar) activation (Takacs and 
Abbott, 2007; Bjork and Wallace, 2009).  Rosen et al. also reported that 
PFOS may modulate various gene expression related to lipid metabolism, 
inﬂammation, and xenobiotic metabolism via Ppar-D independent 
mechanisms, such as the modest activation of constitutive and rostane 
receptor (CAR) and Ppar-J signaling pathway (Rosen et al., 2010).  And 
PFOA was reported to induce various xenobiotic metabolism genes, which 
were under the control of CAR and transcription factor of nuclear factor 
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erythoid 2-related factor 2 (Nrf2) (Rosen et al., 2008).  However, PFOS 
effects on adipogenesis and white adipose tissue expansion is still 
unknown. 
Adipogenesis is a process involving sequential coordinated gene induction 
(Rosen and Spiegelman, 2000).  CCAAT/enhancer-binding protein (Cebp) 
G and Cebp-E induce the expression of Ppar-J, which activates Cebp-D, 
and these two transcriptional factors can work in concert to maintain the 
differentiated status.  Gain-of-function experiments that forced Ppar-J 
and/or in combination with potential agonists demonstrated that non-
adipogenic, fibroblast cells can be transdifferentiated to adipocytes (Wu et 
al., 1995).  Emerging data points to new regulators of Ppar-J expression, 
such as transcription factor of Nrf2, regulated lipid metabolism and the 
process of adipogenesis (Shin et al., 2007; Pi et al., 2010).  Classically, 
Nrf2 binds to antioxidant-responsive elements (ARE), induces expression 
of a battery of detoxification and antioxidant genes to counter cellular 
electrophilic and oxidative stress (Kensler et al., 2007; Klaassen and 
Reisman, 2010).  Pi et al. reported that an ARE element exists in mouse 
Ppar-J promoter, and loss of Nrf2 reduced Ppar-J expression and 
prevented the process of adipogenesis in 3T3-L1 preadipocytes (Pi et al., 
2010).  This work provided a link between Nrf2 and adipogenesis.  Other 
studies have demonstrated that too much Nrf2 activation can also perturb 
adipogeneis.  An early study by Kensler described Nrf2 prevented 
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adipogenesis via modulating Aryl hydrocarbon receptor Signaling (Shin et 
al., 2007).  Our previous results demonstrated that enhanced Nrf2 activity 
via Keap1-knockdown inhibited white adipose tissue expansion and the 
adipocyte differentiation, suggesting the Nrf2-independent mechanism 
involved in Keap1-knockdown (Xu et al., 2012).  Additionally, PFOS 
increased cellular reactive oxygen species (ROS) content, induced the 
antioxidant signaling of Nrf2 and Heme oxygenase-1 (Ho-1) expression 
levels, suggesting the relationship between PFOS administration and Nrf2 
signaling activation (Shi and Zhou, 2010) from in vitro study. 
To evaluate the effect of PFOS on adipogenesis, and further explore its 
effect on regulating white adipose tissue expansion and the development of 
obesity, 3T3-L1 preadipocytes were induced to differentiation to adipocytes 
with the presence of PFOS.  The cellular lipid content and adipogenic gene 
expression was evaluated.  Additionally, glucose uptake was determined in 
the mature adipocytes with PFOS administration.  Lastly, PFOS-induced 
adipogenic effects were also evaluated in a whole animal model with daily 
PFOS administration and in human visceral preadipocytes.  The current 
study demonstrates that PFOS induces Nrf2 activation in association with 
promoting Ppar-J and Cebp-D signaling, and induction of adipogenesis that 
increases lipid accumulation in 3T3-L1 preadipocytes.  Moreover, pro-
adipogenic effects were observed in human visceral preadipocytes 
exposed to PFOS. 
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3.3 MATERIALS AND METHODS 
3.3.1 Chemicals.  Heptadecaperfluorooctanesulfonic acid potassium salt 
(#77282, PFOS), insulin (#I6634), dexamethasone (#D4902, DEX) 
isobutylmethylxanthine (#I5879, IBMX), and Oil Red O (#O0625) were got 
from Sigma-Aldrich (St. Louis, MO).  Ethanol, methanol, and isopropanol, 
MTT solution and other chemicals without specific illustration were got from 
Thermo Fisher Scientific Inc. (Waltham, MA) 
3.3.2 Animals and PFOS administration.  10-week-old male C57BL/6 
mice weighing approximately 30 grams were purchased from Charles River 
Laboratories (Wilmington, MA).  The mice were housed under a controlled 
temperature (22-25 °C) with relative humidity (30-70%), lighting (12 hrs, 
light-dark cycles) environment and acclimated for 5 weeks on the standard 
rodent chow to allow for additional weight gain.  At 15 weeks of age, the 
mice were then fed a purified rodent chow (AIN-93G Growth Purified Diet, 
TestDiet, St. Louis, MO).  At 21 weeks of age, mice (n=8) were 
administered water as vehicle (Veh) via oral gavage (5mL/kg) or PFOS 
(0.1mg/kg, 5mL/kg) for 6 weeks.  Body weight and food intake were 
monitored daily and recorded.  Epididymal white adipose tissue (WAT) was 
collected, snap frozen with liquid nitrogen, and stored at -70°C until 
analysis.  All procedures were conducted in accordance with the NIH 
Guidelines for the Care and Use of Laboratory Animals and were approved 
by the University of Rhode Island Animal Care and Use Committee. 
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3.3.3 Acute cytotoxicity assay.  A minimum of 5 replicates of 7,500 3T3-
L1 preadipocytes per well were plated in 96-well plates and allowed to 
adhere to the plate for approximately 12 hrs, at which time the media was 
removed and replaced with fresh media containing varying concentrations 
of PFOS in DMSO (1nM, 5nM, 10nM, 100nM, 500nM, 1PM, 5 PM, 10PM, 
50PM, 100PM).  Cells were subsequently incubated for an additional 48 
hrs.  Then 20 PL MTT solution (5 mg/mL in PBS) was added and the plate 
was incubated for another 3 hrs.  The supernatant was removed carefully 
and 150 PL MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol) was 
added to each well.  The plate was covered with foil and agitated on an 
orbital shaker for 15 mins.  The cell viability was determined by measuring 
the absorbance at 590 nm with 620 nm as reference filter.  Relative cell 
viability (%) was displayed using vehicle (0.1% DMSO)-treated samples as 
a standard. 
3.3.4 Cell culture and 3T3-L1 pre-adipocyte differentiation.  Mouse 
3T3-L1 (ATCC® CL-173TM) preadipocytes were obtained from ATCC 
(American Type Culture Collection, Manassas, VA, USA) and maintained in 
high-glucose DMEM medium supplemented with 10% fetal bovine serum 
(FBS).  3T3-L1 pre-adipocyte differentiation was induced according to the 
protocol described previously (Shin et al., 2007; Xu et al., 2012).  Briefly, 2 
days post 100% confluence, 3T3-L1 preadipocytes were stimulated to 
differentiation to adipocytes in a standard adipogenic differentiation 
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medium (DMEM containing 10%FBS, 10Pg/mL insulin, 1PM DEX, 0.5mM 
IBMX), which was considered Day 0. Cells were cultured in the latter media 
for Days 0-3 and then cultured in DMEM containing 10%FBS and 10 Pg/mL 
insulin for the remaining days.  Media was refreshed every 2 days.  Cell 
treatment and corresponding assay were described as Figure 1A. 
3.3.5 Human visceral preadipocytes culture and induction to 
adipocytes.  PoieticsTM Human visceral preadipocytes (Donor #: 24711; 
Lot #:0000313366; Cat #: PT-5005) were obtained from Lonza (Lonza 
Walkersville, Inc., Walkersville, MD) and maintained in PBM-2 media 
according to the manufacturer’s instructions.  The preadipocytes were 
plated at 8,700 cells per well.  Cells were induced to differentiation to 
adipocytes by switching with the differentiated media of PBM-2 
supplementing with dexamethasone, isobutylmethylxanthine and 
insulinSingleQuotsTM 24 hrs post 100% confluence and keep in the same 
media for the next 11 days.  Cells were treated with DMSO (0.1%) or PFOS 
(5 or 50PM) in quadruplicates.  Oil red O was used to image the lipid 
droplets.  The cellular lipid was purified via isopropanol extraction and the 
lipid content was quantified spectrophotometrically at what 520 nm.  Cell 
treatment and corresponding assay were described as Figure 1B. 
3.3.6 RNA isolation and quantitative real-time PCR.  Total RNA was 
isolated using TRIzol reagent (Invitrogen, CA) according to the 
manufacturer’s instructions.  One microgram of total RNA was converted to 
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cDNA and mRNA levels were quantiﬁed by quantitative real-time PCR 
using a Roche LightCycler 480 System (Roche Applied Science, 
Mannheim, Germany).  SYBR green chemistry was used and relative target 
gene expression was normalized to 18S rRNA.  The primers used are listed 
in Supplementary Table 1. 
3.3.7 Oil Red O staining.  3T3-L1 preadipocytes or human visceral 
preadipocytes were induced to differentiation to adipocytes.  The 
supernatant was removed and cell layer was washed twice with 2 mL ice-
cold PBS.  Cells were fixed with 10% formalin at 4°C for 30 mins, then 
stained with Oil Red O solution (six parts Oil Red O stock solution [0.5% Oil 
Red O in 100% isopropanol] and four parts H2O) for 60 mins.  Cells were 
counterstained with hematoxylin and mounted in glycerin jelly (Carolina 
Biological Supply Company, Burlington, NC). 
3.3.8 Measurement of triglycerides in 3T3-L1 preadipocytes.  3T3-L1 
preadipocytes plated on 60-mm dishes were induced to adipocytes for 8 
days.  Lipids were extracted according to a previous protocol (Xu et al., 
2012).  Triglycerides content were determined with reagent kits (Pointe 
Scientific, Inc, MI), and the absorbance was measured 
spectrophotometrically at 520 nm.  Relative triglycerides content (%) was 
displayed using differentiation medium containing 0.1% DMSO - treated 
cells as a standard. 
3.3.9 Glucose uptake assay.  Glucose uptake in 3T3-L1 mature 
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adipocytes was measured by using 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) 
amino]-2-deoxy-d-glucose (2-NBDG) according to the manufacturer’s 
instructions (Cayman Chemical Company, MI).  In brief, 3T3-L1 
preadipocytes plated on 96-well fluorescent plates were induced to 
adipocytes as described above.  At Day 11, cells were washed with PBS 
and then treated with serum-free DMEM containing PFOS (0 - 100PM) or 
DMSO (0.1%) for 5 hrs.  Then cells were washed with sterilized PBS for 3 
times, and stimulated with 100 nM insulin for 20 mins in KRPH buffer (20 
mM HEPES, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, 
and 4.7 mM KCl, pH 7.4) with the presence of PFOS or DMSO, 
respectively.  Glucose uptake was initiated by the addition of 100 μg/mL 2-
NBDG to each well.  The fluorescence activity was monitored at an 
excitation wavelength of 485 nm and an emission wavelength of 535 nm.  
At least eight replicates for each dosage was performed.  Relative glucose 
uptake was displayed using vehicle-treated group as a standard. 
3.3.10 hPAP induction assay.  Mouse embryonic fibroblast (MEF) 
differentiation to adipocytes was performed as described elsewhere (Shin 
et al., 2007; Xu et al., 2012).  MEFs were isolated from 13.5- to 15.5-d post 
coital mouse embryos from ARE-hPAP transgenic mice, then cells were 
cultured in DMEM supplemented with 10% FBS in 10 cm culture dishes 
(Johnson et al., 2002).  MEFs were collected and cultured in 6-well plate, 2 
days post of 100% confluence, cells were switched to differentiated media 
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with DMEM containing 10% FBS, 10 Pg/mL insulin, 1 PM DEX, 0.5 mM 
IBMX (Day 0).  Three days later, cells were switched to media only 
containing 10% FBS and 10 μg/mL insulin for the remaining days.  And four 
days post differentiation, total RNA was extracted and the relative mRNA 
levels of hPAP were measured using quantitative real-time PCR.  The 
detailed design was described as Figure 1C. 
3.3.11 Chromatin Immunoprecipitation (ChIP) assay.  3T3-L1 cells were 
induced to adipocytes as described above. Two days post differentiation to 
adipocytes, cells were harvested and the Chip assay was performed 
according to the manufacturer’s instructions (Active Motif, Carlsbad, CA).  
Equal amount of sheared chromatin DNA (15 Pg) was incubated with anti-
Nrf2 antibody (Cell Signaling, Danvers, MA) or IgG as negative control 
overnight at 4°C.  A portion of sheared chromatin DNA was preserved as 
input (10 PL).  Purified DNA was PCR-amplified for 35 cycles (30 s at 94 °C, 
30 s at 59 °C, and 30 s at 72 °C) with the primers that cover putative AREs 
sequences in mouse Nqo-1 promoter.   
(Forward: 5'-GCAGTTTCTAAGAGCAGAACG-3') 
(Reverse: 5'-GTAGATTAGTCCTCACTCAGCCG-3') 
3.3.12 Statistical Analysis.  Quantitative data were presented as average 
± SE.  Statistic differences were determined by a one-way ANOVA followed 
by a Duncan’s Multiple Range post hoc test.  All statistical tests with 
P<0.05 were considered significant. 
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3.4 RESULTS: 
3.4.1 PFOS induces adipogenesis in 3T3-L1 preadipocytes.  In order to 
explore the association of PFOS exposure and adipocyte differentiation, we 
determined the effect of PFOS concentrations on 3T3-L1 pre-adipocyte 
viability.  No overt toxicity was observed at <50PM in the current study 
(Figure 1D).  3T3-L1 preadipocytes were differentiated to adipocytes in the 
presence of differentiated cocktail with or without PFOS.  Oil Red O 
staining of mature lipid-containing adipocytes at Day 8 was performed to 
evaluate PFOS effects on adipogenesis.  Figure 2A illustrates that high 
concentrations of PFOS (1-100PM) increased lipid accumulation in 3T3-L1 
adipocytes compared to vehicle-treated group (Figure 2A).  However, 
staining was similar between vehicle- and PFOS-treated groups treated 
with concentrations less than 1PM (1-500nM), except there was lower lipid 
content at the dosage of 5nM (Figure, 2B, data not shown).  Similar to the 
observed staining, higher PFOS concentrations (1-50PM) increased 
triglyceride content in 3T3-L1 adipocytes by more than 20% above control, 
but this effect was not observed with the relatively lower PFOS 
concentrations (1-100 nM) (Figure 2B).   The data suggest that PFOS has 
the potential to potentiate induction of mouse preadipocyte differentiation to 
mature adipocytes and promote lipid accumulation. 
3.4.2 PFOS increases adipogenic gene expression in 3T3-L1 
preadipocytes.  The underlying molecular mechanisms for PFOS function 
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on adipogenesis were evaluated.  3T3-L1 preadipocytes were induced to 
adipocytes with PFOS administration for continuous 3 days, total RNA was 
extracted and the relative mRNA levels of genes related with adipogenesis 
of Cebp-D, Ppar-J, Fabp4 and Lpl were determined.  There is no significant 
difference for these four genes expression between vehicle- and PFOS-
treated groups at Day1.  After induction to adipocytes for 3 days (Day3), 
Cebp-α, Ppar-J, Fabp4 and Lpl were significantly induced in both groups; 
with induction being significantly higher in PFOS-treated adipocytes than 
vehicle-treated group (increased by 32.2-, 14.2-, 8.6-, and 19.7-fold, 
respectively), suggesting PFOS increased adipogenic gene expression, 
which may contribute to the increased adipogenesis (Figure 3A).  
Additionally, the mRNA levels of Nrf2 and two target genes, Nqo1 and Gclc 
were determined.  After 3 days of induction to adipocytes (Day 3), PFOS 
significantly increased Nrf2, Nqo1 and Gclc mRNA levels in 3T3-L1 
adipocytes than vehicle-treated group by more than 15-fold, suggesting 
that PFOS has the potential to activate Nrf2 signaling in preadipocytes 
(Figure 3B). 
3.4.3 PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 
adipocytes.  In order to assess the metabolic consequence of PFOS 
treatment in 3T3-L1 preadipocytes, insulin-stimulated glucose uptake were 
monitored in vehicle- and PFOS-treated adipocytes.  After 3T3-L1 
preadipocytes were differentiated to adipocytes for 10 days, cells were 
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exposed to PFOS for 5 hrs, then 2-NBDG was added, and the fluorescence 
activity was monitored.  There was no significant difference between the 
low dose PFOS treatments (1 and 5 PM) and vehicle-treated group.  
However, insulin-stimulated glucose uptake was significantly higher in 
PFOS-treated at the concentration of 10 PM than vehicle-treated group (by 
26%).  And a dose-dependent increase of glucose uptake by PFOS-
treatment was observed, with the highest induction being at the dosage of 
100 PM (61.0% higher than vehicle) (Figure 4A).  The gene expression 
related to insulin signaling and glucose metabolism was monitored.  Low 
dose PFOS treatment (1 PM) did not affect Ppar-J, Srebp-1c, Glut4, Irs-1, 
and Insr gene expression.  However, treatment with 10 or 50 PM PFOS 
increased Ppar-J, Srebp-1c, Glut4 and Irs-1 expression compared to 
vehicle-treated group, but with similar Insr expression between vehicle- and 
PFOS-treated groups (Figure 4B).  It was hypothesized that in the early 
induction process, PFOS might induce the antioxidant response, then 
leading to Nrf2 activation that augmented Ppar-J induction (Shi and Zhou, 
2010).  PFOS (1 PM) did not induce Nrf2 or Nqo1 expression, but 
expression was induced by about 30% in cells treated with 10 and 50 PM 
PFOS, suggesting the potential role of PFOS activating Nrf2 signaling in 
mature adipocytes (Figure 4C). 
3.4.4 Adipogenic gene expression and Nrf2 signaling is increased in 
white adipose tissue from mice administered PFOS.  C57BL/6 male 
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mice were administered PFOS for 6 weeks (0.1mg/kg BW/day) and the 
transcript levels corresponding to adipogenesis and Nrf2 signaling were 
measured in epididymal WAT.  PFOS significantly increased the expression 
of adipogenic genes, including Cebp- α, Ppar-J, Fabp4 and Lpl in WAT (by 
66.4%, 93.2%, 73.3%, and 67.6%).  Srebp1c and Insr, related with insulin 
signaling, were significantly induced after PFOS administration (by 67.2% 
and 59.7%), along with the increasing tread of Glut4 and Irs-1 expression 
(by 44.1% and 25.9%) (Figure 5A).  Additionally, PFOS significantly 
induced Nrf2, Nqo1 and Gclc mRNA levels (by 97.2%, 173.0% and 87.3%), 
suggesting enhanced Nrf2 signaling in WAT of mice administrated with 
PFOS.  Expression of Ho-1, Multidrug resistance-associated protein (Mrp) 
2, Mrp4, UDP-glucuronosyltransferase (Ugt) 1a6, and Superoxide 
dismutase-1 (Sod-1), which are highly associated with Nrf2 signaling 
(Thimmulappa et al., 2002; Dreger et al., 2009), were increased in the 
current study.  PFOS decreased Cytochrome P450, family 7, subfamily A, 
polypeptide 1 (Cyp7a1) by 78.5% after PFOS treatment, which is 
consistent with the previous study (Chang et al., 2009). 
3.4.5 PFOS increased lipid accumulation in differentiated human 
visceral preadipocytes.  Human visceral preadipocytes were obtained 
and differentiated to adipocytes, and cellular lipid content was evaluated by 
Oil red O staining.  Eleven days post-differentiation, PFOS (5 and 50 PM) 
significantly increased staining in mature adipocytes (Figure 6A).  
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Furthermore, the stain was extracted and quantified spectrophotometrically.  
Figure 6B illustrates that PFOS increased staining in adipocytes by 48% at 
5 PM and 40% at 50 PM, suggesting PFOS may increase adipogenesis in 
human visceral preadipocytes, contribute to enhance lipid accumulation in 
PFOS-treated group (Figure 6B). 
3.4.6 PFOS increases Antioxidant Response Element activity and 
enhances Nrf2 enrichment at the ARE element in mouse Nqo1 
promoter.  Some recent work indicates that the Nrf2 pathway is inducible 
in MEFs and adipose tissue (Shin et al., 2007; Xu et al., 2012). In order to 
determine whether PFOS induces Nrf2 signaling and might increase 
adipogenesis via the Nrf2 signaling pathway, MEFs from ARE-hPAP 
transgenic mice (Johnson et al., 2002) were isolated and differentiated to 
adipocytes with or without PFOS for 4 days.  Next, hPAP mRNA levels 
were measured by quantitative real-time PCR.  PFOS treatment (50 PM) 
doubled hPAP mRNA levels compared to vehicle controls (Figure 7), highly 
suggesting PFOS increased ARE binding activity (Figure 7A).  
Furthermore, to determine whether the increased ARE binding was via the 
increased Nrf2 binding in PFOS treatment, Chip assay was carried out.  
Figure 7B and 7C illustrate that two days into differentiation, PFOS 
increased Nrf2 binding to ARE sites in mouse Nqo1 promoter (by 31%), 
suggesting that Nrf2 binding was increased after PFOS treatment during 
the differentiation process (Figure 7B, 7C). 
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3.5 DISCUSSION: 
PFOS has been manufactured for over 60 years.  Epidemiological studies 
and recent research with PFOS primarily focuses on widespread exposure 
(Giesy and Kannan, 2001; Olsen et al., 2005), hepatic effects in humans 
(Nelson et al., 2010), primates (Chang et al., 2012) and rodents (Wan et 
al., 2012), and metabolic perturbations (Wan et al., 2012).  However, PFOS 
effects on adipogenesis or adipocyte health is largely undescribed, yet is of 
growing concern because of the growing population of obese people 
worldwide.  In the current study, we demonstrated that PFOS augmented 
adipocyte differentiation, increased the expression of key transcription 
factors of Ppar-J and Cebp-D involved in adipogenesis, and increased ARE 
binding activity and activation of Nrf2 signaling, which increase the binding 
to promoters for oxidative stress-related and adipogenic genes, suggesting 
the potential roles of PFOS regulating white adipose tissue expansion and 
the related obesity. 
The activation of Ppar-J by PFOS suggested that PFOS has Ppar-D 
independent mechanism, which is in agreement with the previous study 
(Rosen et al., 2010).  PFOS increased liver weight and caused 
hypertrophy, which related with the activation of peroxisome proliferator, 
consistent with the effects of Ppar-D activator WY14,643.  Also, PFOS 
induced both mouse and human Ppar-D activation, but exerted a greater 
level of induction of mouse Ppar-D than human Ppar-D at similar 
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concentrations (Takacs and Abbott, 2007).  It has been reported that PFOS 
increased Ppar-J luciferance reporter plasmid activity at the concentration 
from 1 PM to 100 PM, with little toxicity at 250 PM (Takacs and Abbott, 
2007), illustrated that the dose 50 PM used in the current study is the 
optimal concentration for PFOS treatment. 
Ppar-J activation is the key process for adipocyte differentiation in 3T3-L1 
preadipocytes.  Ppar-J is needed for adipose tissue formation in mice, and 
in a loss-of-function experiment, adipocyte differentiation and white adipose 
tissue expansion was impaired, and did not develop glucose intolerance 
and insulin resistance, suggesting the central role for adipogenesis (Jones 
et al., 2005).  We failed to observe adipose tissue expansion in mice 
administered with PFOS (0.1 mg/kg BW/day) for 6 weeks (Data not 
shown).  This lack of effect could be explained by the relatively low dose of 
PFOS has been used in the current study, but is consistent with other 
reports.  Qazi et al. have used 0.005% (W/W) dietary treatment of PFOS 
for 10 days with male mice, resulted in significant reductions for serum 
cholesterol and triglycerides content (Qazi et al., 2010).  And male BALB/c 
mice fed with HFD with the exposure of PFOS at the dose of 5 or 20 mg/kg 
BW/day for 14 days, exhibited reduced serum lipid and lipoprotein content, 
but significantly increased hepatic lipid accumulation, probably via Pparα-
independent pathway (Wang et al., 2014).  Also, compared to liver, PFOS 
deposits to a much lower concentration in white adipose tissue (Maestri et 
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al., 2006).  So perhaps the low dose of PFOS administered might not have 
a positive induction in adipose tissue expansion in vivo, despite this 
treatment inducing adipogenic gene expression at transcriptional levels.  
The second possible reason is that PFOS has a potential function to induce 
Ppar-D activation (Shipley et al., 2004).  Increased Ppar-D in adipose tissue 
could induce lipolysis and promote β-oxidation (Reddy and Hashimoto, 
2001; Goto et al., 2011), which is beneficial to prevent the lipid 
accumulation to adipose tissue and decrease white adipose tissue mass.  It 
was noted that contradict results have been reported that PFOS 
administration reduced white adipose tissue mass, the ventral fat was 
significantly reduced when mice treated with PFOS (20 mg/kg BW/day) for 
14 days, even in normal diet and HFD-group, which related with the 
reduced secretion and impaired function of low density lipoproteins (Wang 
et al., 2014). 
It is interesting to note that PFOS increased insulin-stimulated glucose 
uptake in differentiated adipocytes.  A previous study reported that higher 
serum PFOS concentration was positively associated with increased serum 
insulin levels and insulin resistance (Lin et al., 2009), which contrasts with 
the current study.  And Nelson et al. reported that higher serum PFOA and 
PFOS concentration was positively associated with serum cholesterol 
levels, but displayed a weak association with body weight and insulin 
resistance (Nelson et al., 2010).  Another in vivo study performed on rats, 
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which the pregnant rats were given with PFOS (0.5 or 1.5 mg/kg BW/day) 
from gestation day 0 to postnatal day 21.  The pups displayed impaired 
glucose tolerance and enhanced insulin resistance index, suggesting 
PFOS disrupted insulin signaling in integrate animal study (Lv et al., 2013).  
In the current in vitro study, we demonstrated that PFOS increased insulin-
induced glucose uptake and increased gene expression related to insulin 
signaling.  One possible reason is that PFOS increased adipogenesis in 
3T3-L1 preadipocytes and enhanced adipogenesis increases capacity for 
glucose uptake (Nugent et al., 2001).  Also, enhanced Ppar-J and Glut4 
expression will help to promote glucose uptake, as well as improve insulin 
signaling and insulin-response activity.  Our previous study reported that 
enhanced Nrf2 activity by Keap1-KD increased glucose tolerance, and 
increased insulin-stimulated Akt phosphorylation without Glut4 expression 
change (Xu et al., 2013), suggesting activation Nrf2 can promote insulin 
signaling, contribute to positively regulate glucose uptake in differentiated 
3T3-L1 preadipocytes. 
The study herein reported that PFOS could induce Nrf2 activation in 
preadipocytes.  PFOS administration has been shown to increase ROS 
production, which induces oxidative stress and activate Nrf2 signaling 
(Qian et al., 2010).  ARE consensus elements are the typical transcriptional 
factor binding sites, which are described to induce the antioxidant gene 
expression for Nrf2 target genes, such as Ho1, Gclc, Nqo1, and Multiple 
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resistance-associated proteins to provide a protective role against oxidative 
and cytochemical stress (Nguyen et al., 2009).  Also, ARE sites have been 
reported in the promoter of Pparγ and Cebpα, which are responsible for 
3T3-L1 preadipocytes adipogenesis (Pi et al., 2010).  ARE binding was 
enhanced after PFOS treatment in MEFs isolated from transgenic mice that 
harbor a ARE sequence coupled to a hPAP reporter, suggesting activation 
of genes via ARE sites is a process that occurs via PFOS-induced 
adipogenesis.  Chip assay revealed that PFOS treatment increased Nrf2 
binding to ARE sites in the mouse Nqo1 promoter in 3T3-L1 cells cultured 
in induction media for 4 days, further confirming that PFOS administration 
can induce Nrf2 signaling via ARE binding during adipogenesis. 
Overall, this study reported that novel effects of PFOS in inducing 
Ppar-J and Cebp-D expression and adipogenesis, via enhancing ARE 
binding activity and Nrf2 signaling in preadipocytes (Figure 7D).  
Additionally, PFOS increased insulin-stimulated glucose uptake and 
increased gene expression related with insulin signaling.  This study points 
out the potential roles of PFOS promoting adipose tissue differentiation and 
the related metabolic conditions of obesity consequentially. 
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3.8 FIGURE LEGENDS: 
Figure 1. MTT assay of PFOS on 3T3-L1 preadipocytes.  The illustration 
of study design on (A) 3T3-L1 preadipocytes, (B) human visceral 
preadipocytes, and (C) mouse embryonic fibroblasts.  (D) 3T3-L1 
preadipocytes were exposed to PFOS at concentration of 1nM, 5nM, 10nM, 
100nM, 500nM, 1PM, 5PM, 10PM, 50PM, 100PM or DMSO in DMEM with 
10% FBS for 48 hrs.  PFOS toxicity at different dosage was determined by 
MTT assay.  N=5.  *, P<0.05, PFOS-treated vs. vehicle (Veh). 
 
Figure 2. Non-cytotoxic levels of PFOS enhances lipid content in 
differentiated 3T3-L1 preadipocytes.  Cells were differentiated 2 days 
post 100% confluences (Day 0) by switching with differentiated media 
containing 10Pg/mL insulin, 1PM dexamethasone, 0.5 mM 
isobutylmethylxanthine in DMEM with 10% FBS for the ﬁrst 3 days; then 
switch to media only containing 10 μg/mL insulin in DMEM with 10% FBS 
for the additional 5 days.  Indicated concentration of PFOS or vehicle was 
included in media from Day 0 to Day 8.  (A) Representative images of Oil 
red O staining of 3T3-L1 preadipocytes at indicated concentration of PFOS.  
(B) Lipids were extracted from differentiated 3T3-L1 adipocytes by using 
chloroform/ methanol mixture, and triglycerides (TG) content was 
determined spectrophotometrically.  Relative triglycerides content (%) was 
displayed using differentiated media containing DMSO (0.1%) - treated 
cells as a standard (Veh).  *, P<0.05, PFOS-treated vs. vehicle (Veh). 
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Figure 3. PFOS increases adipogenic gene expression and induced 
Nrf2 signaling in 3T3-L1 preadipocytes.  3T3-L1 preadipocytes were 
induced to differentiation to adipocytes with or without PFOS (50 PM) for 3 
days.  Total RNA was extracted at the indicated time.  Relative mRNA 
levels were quantified by quantitative real-time PCR.  PFOS increased 
adipogenic gene expression of Cebp-D, Ppar-J, Fabp4, Lpl (A), and 
increased Nrf2 signaling of Nrf2, Nqo1, Gclc (B) mRNA levels in 3T3-L1 
preadipocytes  All data were normalized to 18S rRNA levels.  *, P<0.05, 
PFOS-treated vs. vehicle (Veh).. 
 
Figure 4. PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 
adipocytes.  (A) 3T3-L1 preadipocytes were induced to differentiation to 
adipocytes for 10 days, then treated with PFOS (1, 5, 10, 50, 100 PM) for 5 
hrs.  Glucose uptake of differentiated 3T3-L1 preadipocytes was 
determined by using 2-NBDG according to the manufactory instruction.  
The fluorescence activity was monitored at an excitation wavelength of 485 
nm and an emission wavelength of 535 nm.  Relative glucose uptake was 
displayed using vehicle-treated group as a standard.  Total RNA was 
extracted from 3T3-L1 adipocytes after treated with PFOS (10 PM or 50 
PM) for 5 hrs.  Relative mRNA levels of (B) Ppar-J, Srebp-1c, Glut4, Irs-1, 
Insr and (C) Nrf2, Nqo1 were quantified by quantitative real-time PCR.  All 
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data were normalized to 18S rRNA levels.  *, P<0.05, PFOS-treated vs. 
vehicle (Veh). 
 
Figure 5. Adipogenic gene expression and Nrf2 signaling of Nrf2 and 
Nqo1 expression increase in white adipose tissue (WAT) from mice 
administered PFOS.  Mice were administrated with PFOS (0.1mg/kg 
BW/day) for 6 weeks.  Epididymal white adipose tissue was collected and 
total RNA was extracted.  (A, B) Relative mRNA levels of the indicated 
gene were quantified by quantitative real-time PCR.  All data were 
normalized to 18S rRNA levels.  *, P<0.05, PFOS-treated vs. vehicle (Veh). 
 
Figure 6. PFOS increased lipid accumulation in differentiated human 
visceral preadipocytes.  Human visceral preadipocytes obtained from 
Lonza were induced to differentiation to adipocytes by switch with the 
differentiated media contain dexamethasone, isobutylmethylxanthine and 
insulinSingleQuotsTM according to the manufacturer’s instructions, with 
PFOS (5 or 50 PM) or not (0.1% DMSO) for 11 days.  (A) Representative 
images of Oil Red O staining of differentiated human visceral preadipocytes 
treated with PFOS at indicated concentration.  (B) Staining of lipids was 
extracted from differentiated human visceral preadipocytes via isopropanol 
isolation, and the lipid content was determined spectrophotometrically.  
Relative lipid content (%) was displayed using differentiated media 
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containing DMSO (0.1%) - treated cells as a standard (Veh).  *, P<0.05, 
PFOS-treated vs. vehicle (Veh). 
 
Figure 7. PFOS increases hPAP expression and enhances Nrf2 
enrichment at ARE sites in mouse Nqo1 promoter.  (A) Mouse 
embryonic fibroblasts isolated from ARE-hPAP transgenic mice were 
induced to differentiation to adipocytes for 4 days, then incubated with 
PFOS (50 PM) for additional 4 days.  Total RNA was extracted and hPAP 
mRNA levels were quantified by quantitative real-time PCR.  All data were 
normalized to 18S rRNA levels.  *, P<0.05, PFOS-treated vs. vehicle (Veh).  
(B) 3T3-L1 cells were induced to differentiation for 2 days.  Cells were 
collected for chromatin immunoprecipitation assays using either Nrf2 
antibody or IgG as the negative control.  A primer targeted for antioxidant 
response element in mouse Nqo1 promoter was used for PCR 
amplification.  Non-immunoprecipitated chromation (1%) was used as an 
input control.  (C) Relative ChIP signal for PFOS function on Nrf2 
enrichment to ARE element of mouse Nqo1 promoter.  (D) The work-flow 
for PFOS increased adipogenesis via activating Nrf2 signaling and inducing 
Cebp-D, Ppar-J expression in preadipocytes. 
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3.9 FIGURES: 
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3.10 SUPPLEMENTARY MATERIALS: 
Supplementary table 1. Primer sequences for quantitative RT-PCR 
Genes Forward Reverse 
Cebp-α CAAGAACAGCAACGAGTACCG GTCACTGGTCAACTCCAGCAC 
E2m TTCTGGTGCTTGTCTCACTGA CAGTATGTTCGGCTTCCCATTC 
Fabp4 AAGGTGAAGAGCATCATAACCCT TCACGCCTTTCATAACACATTCC 
Glut4 GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG 
Gclc GGGGTGACGAGGTGGAGTA GTTGGGGTTTGTCCTCTCCC 
hPAP TTGCCCCAAATCTCAACTTC TGGGTAGCTGGGACTACAGG 
Insr ATGGGCTTCGGGAGAGGAT GGATGTCCATACCAGGGCAC 
Irs-1 TCTACACCCGAGACGAACACT TGGGCCTTTGCCCGATTATG 
Nqo1 AGGATGGGAGGTACTCGAATC TGCTAGAGATGACTCGGAAGG 
LPL GGGAGTTTGGCTCCAGAGTTT TGTGTCTTCAGGGGTCCTTAG 
Nrf2 TCTTGGAGTAAGTCGAGAAGTGT GTTGAAACTGAGCGAAAAAGGC 
Ppar-J CTCTGTTTTATGCTGTTATGGGTGA GGTCAACAGGAGAATCTCCCAG 
Srebp-1c GCAGCCACCATCTAGCCTG CAGCAGTGAGTCTGCCTTGAT 
18S AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
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SUMMARY AND CONCLUSION 
1. Perinatal peripubertal exposure of bisphenol A increases predisposition to 
NAFLD, in younger as well as adult mice. Developmental exposure of 
environmental chemical like bisphenol A exerts epigenetic modification of 
lipogenic genes.  This gives a novel plausible mechanism of involvement of 
early age epigenetic imprinting for rising prevalence of childhood obesity. 
Childhood lipid homeostasis disturbances may have its roots in perinatal 
toxicity of environmental chemicals. 
2. PFOS exposure augmented differentiation of preadipocytes to adipocytes, 
hence increased overall fat cell number. Thus, indirectly study has 
demonstrated obesogenic property of PFOS.  PFOS also increased 
glucose uptake in adipocytes. 
3. In both BPA induced hepatic steatosis and PFSO induced adipogensis, 
activation of Nrf2 was evident, supporting recent literature stating role of 
Nrf2 in lipid homeostasis.  Using BPA/ PFOS as a model compounds, 
novel mechanism of environmental lipid disturbances through Nrf2 
mediation were elucidated. 
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APPENDIX 1:  
Objective: Studying the hepatic lipid accumulation with short-term high fat diet 
feeding in Keap1 knockdown (Keap1 KD) mice 
Experimental design: Nine week old WT and Keap1 KD mice were fed 10% 
or 60% kCal fat diet for 5 weeks, and then euthanized to collect organs.  
Tissue and serum lipid levels (TG, FFA, LDL/HDL) were detected by 
commercial kits.  For all the figures, differences between the groups were 
calculated by two-way ANOVA followed by Tukey’s multiple comparison tests.  
Asterisk * represents significant difference between WT and Keap1 KD mice, 
whereas # represents significant difference between SD and HFD groups.   
Synopsis: As elaborated in all the manuscripts in this thesis, elucidating role 
of Nrf2 in lipid accumulation is one of the primary goals of my research.  In this 
project, mice having diminished expression of Keap1 protein, and 
subsequently constitutive activation of Nrf2 were utilized.  After 5 weeks on 
HFD, these mice appeared to be protected from lipid accumulation in liver.  
Keap1 KD mice fed SD as well as HFD contained less hepatic lipids as 
compared to WT controls (App 1 fig 2).  TG content of the white adipose 
tissue, on the contrary, was higher in Keap1 KD mice relative to controls, on 
both diets.  On both diets, Keap1 KD mice demonstrated increasing trend in 
LDL/HDL ratio (App 1 fig 2).  Lipogenic target mRNA and protein expression 
was decreased in Keap1 KD mice on SD, and the expression was further 
diminished in HFD fed groups (App 1 fig 4 and 5).  Fatty acid oxidation target 
expression data was inconclusive.  Keap1 KD mice demonstrated high pAmpk 
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α to Ampk α ratio, and this change was higher with HFD (App 1 fig 6).  Ratio of 
pIrs1 to total Irs1 decreased Keap1 KD in SD fed group, but not in HFD fed 
group, compared to respective controls (App 1 fig 6).  
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APPENDIX 2:  
Objective: Studying the effect of perinatal peripubertal (PNPP) effect of 
bisphenol A (BPA) on hepatic lipid accumulation and its mechanism in female 
mice 
Experimental design: Pregnant mice were implanted with osmotic pumps 
containing 250μg/kg BPA or vehicle.  The pups were exposed to BPA after 
birth through milk, and until week 5 of age through drinking water.  One set of 
animals was euthanized at week 5, whereas another set was euthanized at 
week 39, without any further BPA exposure beyond week 5.  The liver tissue 
was used for lipid accumulation (TG, FFA content), mRNA expression (RT-
PCR), protein expression (western blot), promoter methylation (methylated 
DNA immunoprecipitation), and binding assay (chromatin 
immunoprecipitation).  This data is originally a cohort from studies described in 
‘manuscript 2’, hence all the methods have been described in detail.  
Differences between the groups were checked with Student’s t-test, asterisk * 
represents significant difference between BPA treated and vehicle group. 
Synopsis: The treatment group represented here, BPA 250μg/kg is another 
treatment cohort from the same study that is presented in ‘manuscript 2’ of this 
thesis.  Simultaneous study with BPA 25μg/kg and 250μg/kg were performed, 
and data was compared with vehicle group.  Hepatic lipid accumulation (liver 
TG and oil red o staining) was significantly increased with BPA 25μg/kg but not 
with BPA 250μg/kg.  This is the reason study with this exposure level of BPA 
was not included in original manuscript.  Although phenotypic increase in 
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hepatic lipids was not evident in BPA 250μg/kg (App 2 fig 1), lipogenic gene 
expression (App 2 fig 2), protein expression (App 2 fig 3 and 4), Nrf2 signaling 
(App 2 fig 5), and lipogenic promoter hypomethylation (App 2 fig 6) was 
altered similar to BPA 25μg/kg exposure.  Nrf2 binding on the Srebp-1c 
promoter was not enhanced by BPA 250μg/kg exposure (App 2 fig 7), 
indicating transcriptional mechanism of Nrf2 mediated lipid accumulation in 
liver is evident only in BPA 25μg/kg exposure, but not in BPA 250μg/kg.   
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